Field of the Invention
The present invention relates to novel pyrimidones of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their hydrates, their solvates, their pharmaceutically acceptable salts and pharmaceutical ly acceptable compositions containing them. The present invention more particularly novel pyrimidones of the general formula (I).

The present invention also provides a process for the preparation of the above said novel pyrimidones of the formula (I) pharmaceutically acceptable salts, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their hydrates, their solvates, their pharmaceutically acceptable salts, and pharmaceutical compositions containing them.
The novel pyrimidones of the present invention are usefiil for the treatment of inflammation and immunological diseases. Particularly the compounds of the present invention are useful for the treatment of inflammation and immunological diseases those mediated by cytokines such as TNF-a, IL-1, IL-6, IL-lp, IL-8 and cyclooxygenase such as COX-2 and COX-3. The compounds of the present invention are alsc^iiseful for the treatment rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; ischemic heart disease; atherosclerosis; cancer; ischemic-induced cell damage; pancreatic p cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; asthma; muscle degeneration; cachexia; type I and type II diabetes; bone resorption diseases;

ischemia reperftision injury; atherosclerosis; brain trauma; multiple sclerosis; cerebral malaria; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection; and diseases mediated by HIV-1; HIV-2; HIV-3; cytomegalovirus (CMV); influenza; adenovirus; the herpes viruses (including HSV-1, HSV-2) and herpes zoster viruses.
Background of Invention
It has been reported that Cyclooxygenase enzyme exists in three isoforms, namely, COX-1, COX-2 and COX-3. COX-1 enzyme is essential and primarily responsible for the regulation of gastric fluids whereas COX-2 enzyme is present at the basal levels and is reported to have a major role in the prostaglandin synthesis for inflammatory response. These prostaglandins are known to cause inflaimnation in the body. Hence, if the synthesis of these prostaglandins is stopped by way of inhibiting COX-2 enzyme, inflammation and its related disorders can be treated. COX-3 possesses glycosylation-dependent cyclooxygenase activity. Comparison of canine COX-3 activity with murine COX-1 and COX-2 demonstrated that this enzyme is selectively inhibited by analgesic/antipyretic drugs such as acetaminophen, phenacetin, antipyrine, and dipyrone, and is potently inhibited by some nonsteroidal antiinflammatory drugs. Thus, inhibition of COX-3 could represent a primary central mechanism by which these drugs decrease pain and possibly fever. Recent reports show that inhibitors of COX-1 enzyme causes gastric ulcers, where as selective COX-2 and COX-3 enzyme inhibitors are devoid of this function and hence are found to be safe.
The present invention is concerned with treatment of immunological diseases or inflammation, notably such diseases are mediated by cytokines or cyclooxygenase. The principal elements of the immune system are macrophages or antigen-presenting cells, T cells and B cells. The role of other immune cells such as NK cells, basophils, mast cells and dendritic cells are known, but their role in primary immunologic

disorders is uncertain. Macrophages are important mediators of both inflammation and providing the necessary "help" for T cell stimulation and proliferation. Most importantly macrophages make IL-1, IL-12 and TNF-a all of which are potent pro¬inflammatory molecules and also provide help for T cells. In addition, activation of macrophages results in the induction of enzymes, such as cyclooxygenase-2 (COX-2) and cyclooxygenase-3 (COX-3), inducible nitric oxide synthase (iNOS) and production of free radicals capable of damaging normal cells. Many factors activate macrophages, including bacterial products, superantigens and interferon gamma (IFNy). It is believed that phosphotyrosine kinases (PTKs) and other undefined cellular kinases are involved in the activation process.
Cytokines are molecules secreted by immune cells that are important in mediating immune responses. Cytokine production may lead to the secretion of other cytokines, altered cellular function, cell division or differentiation. Inflammation is the body's normal response to injury or infection. However, in inflammatory diseases such as rheumatoid arthritis, pathologic inflammatory processes can lead to morbidity and mortality. The cytokine tumor necrosis factor-alpha (TNF-a) plays a central role in the inflammatory response and has been targeted as a point of intervention in inflammatory disease. TNF-a is a polypeptide hormone released by activated macrophages and other cells. At low concentrations, TNF-a participates in the protective inflammatory response by activating leukocytes and promoting their migration to extravascular sites of inflammation (Moser et al., J Clin Invest, 83, 444-55,1989). At higher concentrations, TNF-a can act as a potent pyrogen and induce the production of other pro-inflammatory cytokines {Haworth et al., Eur J Immunol, 21, 2575-79, 1991; Brennan et ah. Lancet, 2, 244-7, 1989). TNF-a also stimulates the synthesis of acute-phase proteins. In rheumatoid arthritis, a chronic and progressive inflammatory disease affecting about 1% of the adult U.S. population, TNF-a mediates the cytokine cascade that leads to joint damage and destruction

(Arend et al. Arthritis Rheum, 38, 151-60, 1995). Inhibitors of TNF-a, including soluble TNF receptors (etanercept) (Goldenberg, Clin Ther, 21, 75-87, 1999) and anti-TNF-a antibody (infliximab) (Luong et ai, Ann Pharmacother, 34, 743-60, 2000), have recently been approved by the U.S. Food and Drug Administration (FDA) as agents for the treatment of rheumatoid arthritis.
Elevated levels of TNF-a have also been implicated in many other disorders and disease conditions, including cachexia, septic shock syndrome, osteoarthritis, inflammatory bowel disease such as Crohn's disease and ulcerative colitis etc.
Elevated levels of TNF-a and/or IL-1 over basal levels have been implicated in mediating or exacerbating a number of disease states including rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; pancreatic p cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; asthma; muscle degeneration; cachexia; type I and type II diabetes; bone resorption diseases; ischemia reperfusion injury; atherosclerosis; brain trauma; multiple sclerosis; cerebral malaria; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection. HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses (including HSV-1, HSV-2), and herpes zoster are also exacerbated by TNF-a.
It can be seen that inhibitors of TNF-a are potentially useful in the treatment of a wide variety of diseases. Compounds that inhibit TNF-a have been described in several patents.
Excessive production of IL-6 is implicated in several disease states, it is highly desirable to develop compounds that inhibit IL-6 secretion. Compounds that inhibit IL-6 have been described in U.S. Pat. Nos. 6,004,813; 5,527,546 and 5,166,137.

The cytokine IL-1P also participates in the inflammatory response. It stimulates thymocyte proliferation, fibroblast growth factor activity, and the release of prostaglandin from synovial cells. Elevated or unregulated levels of the cytokine IL-lp have been associated with a number of inflammatory diseases and other disease states, including but not limited to adult respiratory distress syndrome, allergy, Alzheimer's disease etc. Since overproduction of IL-lp is associated with numerous disease conditions, it is desirable to develop compounds that inhibit the production or activity of IL-lp.
In rheumatoid arthritis models in animals, multiple intra-articular injections of lL-1 have led to an acute and destructive form of arthritis (Chandrasekhar et al., Clinical Immunol Immunopathol. 55, 382, 1990). In studies using cultured rheumatoid synovial cells, IL-] is a more potent inducer of stromelysin than TNF-a. (Firestein, Am. J. Pathol. 140, 1309, 1992). At sites of local injection, neutrophil, lymphocyte, and monocyte emigration has been observed. The emigration is attributed to the induction of chemokines (e.g., IL-8), and the up-regulation of adhesion molecules (Dinarello, Eur. Cytokine Netw. 5, 517-531, 1994).
In rheumatoid arthritis, both IL-1 and TNF-a induce synoviocytes and chondrocytes to produce coUagenase and neutral proteases, which leads to tissue destruction within the arthritic joints. In a model of arthritis (collagen-induced arthritis (CIA) in rats and mice) intra-articular administration of TNF-a either prior to or after the induction of CIA led to an accelerated onset of arthritis and a more severe course of the disease (Brahn et al., Lymphokine Cytokine Res. 11, 253, 1992; and Cooper, Clin. Exp.Immunol. 898, 244, 1992).
IL-8 has been implicated in exacerbating and/or causing many disease states in which massive neutrophil in filtration into sites of inlammation or injury (e.g., ischemia) is mediated chemotactic nature of IL-8, including, but not limited to, the following: asthma, inflammatory bowl disease, psoriasis, adult respiratory distress

syndrome, cardiac and renal reperfusion injury, thrombosis and glomerulonephritis. In addition to the chemotaxis effect on neutrophils, IL-8 has also has ability to activate neutrophils. Thus, reduction in IL-8 levels may lead to diminished neutrophil infiltration.
Few prior art references, which disclose the closest compounds, are given here:
i) US patent Nos. 5,726,124 and 5,300,477 disclose novel herbicidal compounds of formula (Ila)
R2 is a substituted or unsubstituted aryl group or a substituted or unsubstituted
heteroaromatic group {e.g. a heteroaromatic ring structure having four to five carbon
atoms and one heteroatom selected from the group consisting of nitrogen, sulfur and
oxygen); R3 is an alkyl, haloalkyl, polyhaloalkyl, haloalkenyl, polyhaloaikenyl,
alkenyl, alkynyl, haloalkynyl, polyhaloalkynyl, alkoxyalkyl, dialkoxyalkyl,
haloalkoxyalkyl, oxoalkyl, trimethylsilylalkynyl, cyanoalkyl or aryl group; R3 is a
hydrogen, halo, acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkoxyalkyl,
alkoxyimino, alkoxycarbonylalkyl, dialkoxyalkyl, formyl, haloalkyl, haloalkenyl,
haloalkynyl, haloalkoxy, hydroxyalkyl, hydroxyimino, polyhaloalkyl,
polyhaloaikenyl, polyhaloalkynyl, polyhaloalkoxy, trimethylsilylalkynyl,
alkoxyalkoxy, aminocarbonylaJkyl, alkylaminocarbonylalkyl,
dialkylaminocarbonylalkyl, cyanoalkyl, hydroxy or cyano group; and R^ is a hydrogen, halo, alkyl, alkenyl, alkynyl, alkoxy, aikylthio, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, haloalkyl, haloalkenyl, haloalkynyl, haloalkoxy, haloalkylthio, polyhaloalkyl, polyhaloaikenyl, polyhaloalkynyl, polyhaloalkoxy, polyhaloalkylthio, cycloalkyl, aryl, aryloxy, heterocyclyl, aralkyl,

alkj'lamino, dialkylamino, dialkylaminocarbonyl, or cyano group; and X is oxygen or sulfur.
An example of these compounds is shown in formula (lib)

ii) US patent No. 5,474,996 discloses novel compounds of formula (lie)
R5 is a single bond or "(CHz)^ -, -NH-, etc., m is an integer of 0 to 4; Y is Yi-B-Yj is a monocyclic aryl of 5 to 6 ring member or condensed ring of 8 to 10 ring members optionally containing at least one heteroatom chosen from oxygen, nitrogen and sulfur; Rio and Rn together form 0x0 group; R2 is chosen from the group consisting of hydrogen, halogen, hydroxyl, mercapto, cyano, nitro, formyl, benzoyl, acyl of 1 to 6 carbon atoms, alkyl, alkenyl, alkoxy, alkylthio of up to 10 carbon atoms, phenyl, phenoxy, naphthyl, benzyl, phenylthio, biphenyl, biphenylmethyl and indole; R3 is alkyl substituted with carboxy or esterified carboxy. An example of these compounds is shown in formula (lid)


X is 0, S or NR5; Ri and R2 are each independently represent ~Y or —Z—Y, and R3 and R4 are each independently -Z-Y or R3 is a hydrogen radical; provided that R4 is other than a substituted-aryl, (substituted-aryl)methyl or {substituted-aryl)ethyl radical; wherein each Z is independently optionally substituted alkyl, alkenyl, alkynyl, heterocyclyl, aryl or heteroaryl; Y is independently a hydrogen; halo, cyano, nitro, etc., Rj is independently a hydrogen, optionally substituted alkyl, alkenyl, alkynyl etc., Rn and R12 each independently represent optionally substituted aryl or heteroaryl.
An example of these compounds is shown in formula (Ilf)


wherein Ri is H, alkyl, alkenyl, dialkylaminoalkyl, or aralkyl; R2 is H, alkyl, aryl, or halogen; R3 is alkyl, alkenyl, cycloalkyl, aralkyl, aralkenyl, or aryl, R4 is alkyl, alkenyl, cycloalkyl, aralkyl, aryl, etc.
An example of these compounds is shown in formula (IIj)


Ri is alkyl, alkenyl, alkynyl, cycloalkyl, NR4R5 etc., R2 is hydrogen, halogen, SR4, etc., R3 is R4, —COOR, —CONH2, CN, etc., R4, R5 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl etc., or R4 and R5 together with the carbon atoms to which they are attached form a carbonyl or a thiocarbonyl group; R^ is ~CN, alkyl, acyloxy, SO2NH2, aryl, furyl; R7 is H, halogen, etc., Ra is H, halogen, alkyl, alkoxy etc.,
An example of these compounds is shown in formula (III)


Objective of the Invention
We have focused our research to identify selective COX-2 and COX-3 inhibitors which are devoid of any side effects normally associated with anti¬inflammatory agents. Our sustained efforts have resulted in novel pyrimidones of the formula (I). The derivatives may be useful in the treatment of inflammation and immunological diseases. Particularly the compounds of the present invention are useful for the treatment of inflammation and immunological diseases those mediated by cytokines such as TNF-a, IL-1, IL-6, IL-ip, IL-8 and cyclooxygenase such as COX-2 and COX-3. The compounds of the present invention are also useful in the treatment of rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; ischemic heart disease; atherosclerosis; cancer; ischemic-induced cell damage; pancreatic P-cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; asthma; muscle degeneration; cachexia; type I and type II diabetes; bone resorption diseases; ischemia reperiusion injury; atherosclerosis; brain trauma; multiple sclerosis; cerebral malaria; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection; and diseases mediated by HIV-1; HIV-2; HIV-3; cytomegalovirus (CMV); influenza; adenovirus; the herpes viruses (including HSV-1, HSV-2) and herpes zoster viruses.
Summary of tlie Invention
The present invention relates to novel pyrimidones of the formula (I)


their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, and their pharmaceutically acceptable salts, wherein X represents oxygen, sulfur or NR, wherein R represents hydrogen, hydroxyl, acyl, alkyl, alkoxy, aryl, amino, hydroxyl amino, alkylamino, arylamino, acylamino, alkoxyamino group; the rings represented by A and B are selected from aryl or heteroaryl; R' and R^ may be same or different and independently represent hydrogen, SR^, S{0)pR^; R^ and R"* may be same or different and independently represent hydrogen, halogen, hydroxyl, nitro, cyano, azido, nitroso, amino, formyl, alkyl, haloalkyl, acyl, alkoxy, monoalkyiamino, dialkylamino, acylamino, alkoxycarbonyl, SR', S(0)pR^, alkoxyalkyl groups or carboxylic acids or its derivatives; R^ and R*^ may be same or different and independently represent hydrogen, halogen, hydroxyl, nitro, cyano, azido, nitroso, amino, formyl, alkyl, aryl, aralkyl, haloalkyl, acyl, alkoxy, aryloxy, aralkoxy, heteroaryl, heterocyclyl, monoalkyiamino, dialkylamino, acylamino, alkoxycarbonyl, SR^, S(0)pR^ alkoxyalkyl groups or COR^; R^ represents hydrogen, alkyl or aryl; R^ represents halogen, alkyl, amino, acylamino, arylamino or aryl group; R^ represents hydrogen, hydroxyl, amino, halogen, alkyl, alkoxy, aryloxy, monoalkyiamino, dialkylamino, acylamino, arylamino, groups; m is an integer and is in the range of 0 to 4; n is an integer and is in the range of 0 to 4; p represents an integer of 1 or 2; with a proviso that when R' represents hydrogen R^ is not hydrogen.
Detailed Description of the Invention Suitable ring systems represented by A and B are selected from phenyl, naphthyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl, piperazinyl, pyridyl, thienyl, furyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl.

oxadiazolyl, thiadiazolyl, tetrazolyl, pyrimidinyl, benzopyranyl, benzofuranyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, benzopyrrolyl, benzoxadiazolyl, benzothiadiazoiyi, quinolinyl, isoquinolinyl, benzothienyl, benzofiiranyl, indolyl and the like.
Suitable groups represented by R' and R^ are selected from hydrogen, SR^, or S(C)pR^
Suitable groups represented by R^ and R** are selected from hydrogen, halogen atom such as fluorine, chlorine, bromine, iodine; hydroxyl, nitro, cyano, azido, nitroso, amino, formyl, linear or branched (Q-C^) alkyl group, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, isopentyl, hexyl and the like; haloalkyl such as chloromethyl, chloroethyl, trifluoromethyl, trifluoroethyl, dichloromethyl, dichloroethyl and the like; acyl group such as -C(=0)CH3, -C(=0}C2H5, -C(=0)C3H7, -C(=0)C6Hi3, -C(=S)CH3, -CC=S)C2H5, -C(=S)C3H7, -C(=S)C6H|3, benzoyl; linear or branched (Ci-C^) alkoxy group, such as methoxy, ethoxy, n-propoxy, isopropoxy and the like; monoalkylamino group such as NHCHj, NHC2H5, NHC3H7, NHCSHB, and the like; dialkylamino group such as N(CH3)2, NCH3{C2H5), N(C3H5)2 and the like; acylamino group such as NHC(=0)CH3, NHC(=0)C2H5, NHC(=0)C3H7, NHC(=0)C6H|3, and the like; alkoxycarbonyl group such as methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl and the like; alkoxyalkyl group such as methoxymethyl, ethoxymethyl, methoxyethyl, ethoxyethyl and the like; carboxylic acid or its derivatives such as esters, amides and acid halides, SR , or S(0)pR .
Suitable groups represented by R^ and R* are selected from hydrogen, halogen atom such as fluorine, chlorine, bromine, iodine; hydroxyl, nitro, cyano, azido, nitroso, amino, formyl, linear or branched (C|-C6) alkyl group, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, isopentyl, hexyl and the like; haloalkyl such as wherein the alkyl is as defined above; aryl such as phenyl, naphthyl

and the like; aralkyl such as benzyl, phenylethyl, phenylpropyl and the like; aryloxy group such as phenoxy, napthoxy and the like; aralkoxy group such as phenylmethoxy, phenylethoxy, phenylpropoxy, and the like; heteroaryl group such as pyridyl, thienyl, ftiryl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, isooxazolyl, oxadiazolyl, triazolyl, thiadiazolyl, tetrazolyl, pyrimidinyl, benzopyranyl, benzofuranyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, benzopyrrolyl, benzoxadiazolyl, benzothiadiazolyl and the like; heterocyclyl group such as pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl, piperazinyl, and the like; acyl group such as -C(=0)CH3, -C(=0)C2H5, -C(=0)C3H7, -C(=0)C6H,3, -C(=S)CH3, -C(=S)C2H5, -C(=S)C3H7. -C(=S)C6H,3, benzoyl; linear or branched (Ci-Cs) alkoxy group, such as methoxy, ethoxy, n-propoxy, isopropoxy and the like; monoalkylamino group such as NHCH3, NHC2H5, NHC3H7, NHC6H13, and the like; dialkylamino group such as N{CH3)2, NCH3(C2H5), N(C2H5)2 and the like; acylamino group such as NHC(=0)CH3, NHC(=0)C2H5, NHC(=0)C3H7, NHC{=0)C6Hi3, and the like; alkoxycarbonyl group such as methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl and the like; alkoxyalkyl group such as methoxymethyl, ethoxymethyl, methoxyethyl, ethoxyethyl and the like or COR*, SR^ or S(0)pR^
The groups represented by R^ and R^ may be substituted with the substituents selected from halogen, hydroxyl, nitro, cyano, azido, nitroso, amino, formyl, alkyl, aryl, aralkyl, haloalkyl, acyl, alkoxy, aryloxy, aralkoxy, heteroaryl, heterocyclyl, monoalkylamino, dialkylamino, acylamino, alkoxycarbonyl, alkylsulfonyl, alkylsulfmyl, alkylsulfanyl, sulfamoyl, alkoxyalkyl groups or carboxylic acids or its derivatives. The substituents are as defined above.
Suitable groups represented by R^ are selected from hydrogen, linear or branched (Ci-C6)alkyl group, such as methyl, ethyl, n-propyl, isopropyl, n-butyl.

isobutyl, t-butyl, n-pentyl, isopentyl, hexyl and the like; aryl group such as phenyl or naphthyl.
Suitable groups represented by R^ are selected from amino, halogen atom such as fluorine, chlorine, bromine, iodine; linear or branched {Ci-C6)alkyl group, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, isopentyl, hexyi and the like; aryl group such as phenyl or naphthyl; arylamino such as phenyl amino, naphthyl amino and the like; acylamino group such as NHC(=0)CH3, NHC(-0)C2H5, NHC(=0)C3H7, NHC{=0)C6H,3, and the like.
Suitable groups represented by R^ are selected from hydrogen, hydroxyl, amino, halogen atom such as fluorine, chlorine, bromine, iodine; linear or branched (CrC6)alkyl group, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, isopentyl, hexyl and the like; linear or branched (Ci-Ce) alkoxy group, such as methoxy, ethoxy, n-propoxy, isopropoxy and the like; monoalkylamino group such as NHCH3, NHC2H5, NHC3H7, NHCeHn, and the like, which may be substituted; dialkylamino group such as N(CH3)2, NCHsCCjHs), N(C2H5)2 and the like; aryloxy group such as phenoxy, napthoxy and the like; arylamino such as phenyl amino, naphthyl amino and the like; acylamino group such as NHC(=0)CH3, NHC(=0)C2H5, NHC{=0)C3H7, NHC(=0)C6Hi3, and the like.
Suitable groups represented by R are selected from hydrogen, hydroxyl, amino, hydroxylamino, linear or branched (Ci-C6)alkyl group, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, isopentyl, hexyl and the like; linear or branched (Ci-Ce) alkoxy group, such as methoxy, ethoxy, n-propoxy, isopropoxy and the like; aryl group such as phenyl, naphthyl and the like; acyl group such as -C(=0)CH3, -C{=0)C2H5, -C(=0)C3H7. -C{=0)C6H,3, -CC=S)CH3, -C(-S)C2H5, -C(-S)C3H7, -C(=S)C6H,3, benzoyl; aryl group such as phenyl or naphthyl; alkylamino group such as NHCH3, NHC2H5, NHC3H7. NHCeHij, N(CH3)2, NCH3(C2H5), N(C2H5)2 and the like; acylamino group such as NHC(=0)CH3,

NHC(-0)C2H5, NHC(=0)C3H7, NHC(=0)C6H,3, and the like; atylamino such as phenyl amino, naphthyl amino and the Hke; alkoxyamino such as methoxyamino, ethoxyamino, propoxy amino and the like.
m and n are integers ranging from 0-4.
Pharmaceutical ly acceptable salts of the present invention include alkali metal salts like Li, Na, and K salts, alkaline earth metal salts like Ca and Mg salts, salts of organic bases such as diethanolamine, a-phenylethylamine, benzylamine, piperidine, morpholine, pyridine, hydroxyethylpyrrolidine, hydroxyethylpiperidine, guanidine, choline and the like, ammonium or substituted ammonium salts, aluminum salts. Salts also include amino acid salts such as glycine, alanine, cystine, cysteine, lysine, arginine, phenylalanine etc. Salts may include sulphates, nitrates, phosphates, perchlorates, borates, hydrohalldes, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, tosylates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, ketoglutarates and the like. Pharmaceutically acceptable solvates may be hydrates or comprising other solvents of crystallization such as alcohols.
Representative compounds according to the present invention include: 5-Cyano-2-(4-chlorophenyl)-4-(methyIthio)-l-[4-(niethylthio)phenyl]-6-oxo-l,6-dihydropyrimidine;
5-Cyano-2-(4-fluorophenyl)-4-(methylthio)-l-[4-(methylthio)phenyl]-6-oxo-l,6-dihydropyrimidine ; 5-Cyano-2-phenyl-4-{methylthio)-l-[4-(methylthio)phenyl]-6-oxo-l,6-
dihydropyrimidine ;
5-Cyano-2-(trifluoromethylphenyl)-4-(methylthio)-l-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine;

5-Cyano-2-[(4-methylthio)phenyl]-4-{methylthio)-l-[4-fluorophenyl]-6-oxo-l,6-
dihydropyrimidine;
5 -Cyano-1 -(4-methylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1,6-
dihydropyrimidine
5-Cyano-2-[{4-methylsulfonyl)phenyI]-4-(methyIthio)-l-[4-methylphenyl]-6-oxo-
1,6-dihydropyrimidine;
5-Carboxy-2-[(4-inethylthio)phenyl]-4-(methylthio)-l-[4-methylphenyl]-6-oxo-l,6-
dihydropyrimidine;
5-Cyano-l-(4-isopropylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-l,6-
dihydropyrimidine;
5-Cyano-1 -(3,4-dimethylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1,6-
dihydropyrimidine;
5-Cyano-l-{4-isopropylphenyl)-2-[4-(methylsulfonyl)phenyl]-4-(methylthio)-6-oxo-
1,6-dihydropyrimidine;
5-Cyano-l-(3,4-dimethyJphenyJ)-2-[4-(methyIsulfonyl)phenyl]-4-(methylthio)-6-
0X0-1,6-dihydropyrimidine;
5-Cyano-l-{3,4,5-trimethoxyphenyl)-4-{methylthio)-2-[4-(niethylthio)phenyl]-6-oxo-
1,6-dihydropyrimidine;
5-Cyano-l-(4-ethylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyI]-6-oxo-I,6-
dihydrop3aimidine;
l-(4-Bromophenyl)-5-cyano-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-l,6-
dihydropyrimidine;
5-Cyano-l-(4-methoxyphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-l,6-
dihydropyrimidine;
5-Cyano-1 -(4-fluorophenyl)-4-(methyIthio)-2-phenyJ-6-oxo-1,6-dihydropyrimidine;
l-(4-Chlorophenyl)-5-cyano-4-{methylthio)-2-[4-(methylthio)phenyl]-6-oxo-l,6-
dihydropyrimidine;

5-Cyano-1 -(2,4-diinethylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine;
5-Cyano-2-(4-methylphenyl)-4-(methylthio)-l-[4-(methylthio)phenyl]-6-oxo-l,6-dihydropyrimidine;
5-Cyano-1 -(4-methoxyphenyI)-4-(methyIthio)-2-[4-(methyIthio)phenyI]-6-oxo-1,6-dihydropyrimidine;
l-(4-tert-Butylphenyl)-5-cyano-4-(methylthio)-2-t4-(methylthio)phenyI]-6-oxo-I,6-dihydropyrimidine;
5-Cyano-1 -(4-TnethyIphenyl)-4-(methylthio)-6-oxo-2-phenyl-1,6-dihydropyrimidine; 1 -(4-n-Butylphenyl)-5-cyano-4-(methyldiio)-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine;
5-Cyano-1 -(4-fluorophenyl)-4-(methylthio)-6-oxo-2-pyridin-4-yl-1,6-dihydropyrimidine;
5-Cyano-l-(4-fluorophenyl)-4-{methyhhio)-6-oxo-2-pyridin-3-yl-l,6-dihydropyrimidine;
5-Cyano-4-(methylthio)-l-[4-(methylthio)phenyl]-6-oxo-2-pyridin-3-yl-l,6-dihvdropyrimidine;
5-Cyano-4-(methylthio)-l-[4-(methy!thio)phenyl]-6-oxo-2-p)Tidin-4-yl-l,6-dibydropyrimJdine;
5-Cyano-l-(4-fluorophenyl)-4-(methyltiiio)-6-oxo-2-pyridin-2-yl-l,6-dihydropyrimidine;
5-Cyano-4-(methylthio)-l-[4-(methylthio)phenyl]-6-oxo-2-pyridin-2-yl-l,6-dihydropyrimidine;
5-Cyano-4-(methylthio)-1 -{4-methoxyphenyl)-6-oxo-2-pyridin-2-yl-1,6-dihydropyrimidine;
5-Cyano-4-(methylthio)-l-(3,4-dimethylphenyI)-6-oxo-2-pyridin-2-yl-l,6-dihydropyrimidine;

5-Cyano-4-{methyIthio)-l-{4-ethyIphenyI)-6-oxo-2-pyridin-2-yI-l,6-
dihydropyrimidine;
5-Cyano-4-(methylthio)-l-(4-methy]pheny!)-6-oxo-2-pyridin-2-yl-l,6-
dihydropyrimidine;
5-Cyano-4-(methylthio)-l-(4-ethoxyphenyl)-6-oxo-2-pyridin-4-yl-l,6-
dihydropyrimidine;
5-Cyano-4-(methylthio)-l-{4-methylphenyl)-6-oxo-2-pyridin-4-yl-l,6-
dihydropyrimidine;
5-Cyano-4-{methyIthio)-1 -C4-isopropyIphenyl)-6-oxo-2-pyridin-4-yI-1,6-
dihydropyrimidine;
5-Cyano-4-(methylthio)-1 -C4-ethylphenyl)-6-oxo-2-pyridin-3-yl-1,6-
dihydropyrimidine;
5-Cyano-4-(methylthio)-l-(3,4-dimethylphenyl)-6-oxo-2-pyridin-3-yI-l,6-
dihydropyrimidine;
5-Cyano-4-(methylthio)-l-(4-methoxyphenyl)-6-oxo-2-pyridin-3-yl-l,6-
dihydropyrimidine;
Ethyl i -(4-methylphenyi)-4-(methylthio)-2-[4-(methyithio)phenyl]-6-oxo-1,6-
dihydropyrimidine-5-carboxylate;
Ethyl l-(4-fluorophenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-l,6-
dihydropyrimidine-5-carboxylate;
Ethyl 2-(4-fluorophenyl)-4-(methylthio)-l-[4-(methylthio)phenyl]-6-oxo-l,6-
dihydropyrimidine- 5 -carboxylate;
S-Carboxamido-l-(4-methylphenyl)-4-(inethylsulfonyl)-2-[4-
(methylsulfonyl)phenyl]-6-oxo-1,6-dihydropyrimidine;
5-Carboxamido-l-(4-methylphenyI)-2-[4-(methylsulfonyJ)phenyI]-6-oxo-4-
piperazin-l-yl-l,6-dihydropyrimidine;

5-Carboxamido-4-(methy]ainino)-l-(4-methylphenyl)-2-[4-(methylsu]fonyl)phenyl]-
6-0x0-1,6-dihydropyrimidine;
5-Carboxamido-l-(4-methylphenyl)-2-[4-{methylsulfonyl)phenyl]-4-morpholin-4-yl-
6-0X0-1,6-dihydropyrimidine;
5-Carboxamido-2-{4-fluorophenyI)-4-(methylsulfonyl)-l-[4-
(methylsulfonyl)phenyI]-6-Qxo-! ,6-dihydropyrimidine;
5-Carboxamido-2-(4-fluorophenyl)-4-(methylaniino)-l-[4-(methylsulfonyl)phenyl]-
6-0X0-1,6-dihydropyrimidine;
5-Carboxainido-2-(4-fluorophenyl)-l-[4-{methylsulfonyl)phenyl]-4-morpholin-4-yl-
6-0X0-1,6-dihydropyrimidine;
5-Carboxamido-1 -(3,4-dimethyIphenyi)-4-(methyIsuIfonyl)-2-[4-
(methy]sulfonyl)phenyl}-6-oxo-],6-dihydropyrimidine;
5-Cyano-2-(4-fluorophenyl)-4-hydroxy-l-[4-(methylsulfonyl)phenyl]-6-oxo-l,6-
dihydropyrimidine;
5-Cyano-l-(3,4-dimethylphenyl)-4-hydroxy-2-[4-(methylsulfonyl)phenyl]-6-oxo-l,6-
dihydropyrimidine;
5-Cyano-4-(methyJamino)-l-(4-methyIphenyi)-2-[4-(methyIthio)phenyl]-6-oxo-l,6-
dihydropyrimi din e;
5-Cyano-1 -(3,4-dimethylphenyl)-4-(methylamino)-2-[4-(methylthio)phenyl]-6-oxo-
1,6-dihydropyrimidine;
5-Cyano-2-(4-fluorophenyl)-4-(methylaraino)-l-[4-(methylthio)phenyl]-6-oxo-l,6-
dihydropyrimidine;
4-[5-Cyano-I-(3,4-dimethyIphenyI)-4-(methylthio)-6-oxo-l,6-dihydropyrimidin-2-
yljbenzenesulfonyl chloride;
4-[5-Cyano-2-(4-ethoxyphenyl)-4-(methyUhio)-6-oxopyrimidin-l(6//)-
yl]benzenesulfonyl chloride;

4-[5-Cyano-l-(4-methylphenyl)-4-(methylthio)-6-oxo-l,6-dihydropyrimidin-2-
yl]benzenesulfonamide;
A^-({4-[5-Cyano-l-(4-methyIphenyI)-4-(methyIthio)-6-oxo-I,6-dihydropyrimidin-2-
yl]phenyl}sulfonyl)acetamide;
Ai'-({4-[5-Cyano-l-(3,4-dimethylphenyl)-4-(methylthio)-6-oxo-l,6-dihydropyrimidin-
2-yl]phenyl} sulfonyl)acetamide;
7*/-{{4-[5-Cyano-l-(4-methylphenyl)-4-(methylthio)-6-oxo-l,6-dihydropyrimidin-2-
yl]phenyI}sulfonyl)-2,2,2-trifluoroacetamide;
W-{{4-[5-Cyano-l-(3,4-dimethylphenyl)-4-(methylthio)-6-oxo-l,6-dihydropyrimidin-
2-yl]phenyl}sulfonyl)-2,2,2-trifluoroacetamide;
A'-({4-[5-Cyano-l-{4-methylphenyl)-4-(methylthio)-6-oxo-l,6-dihydropyrimidin-2-
yI]phenyI}suIfonyl)benzamide and
7V-({4-[5-Cyano-]-(3,4-dimethylpheny])-4-{niethyltbio)-6-oxo-],6-d)hydropyTimidin-
2-yl]phenyl} sulfonyl)benzamide.
According to another embodiment of the present invention, there is provided a process for the preparation of novel pyrimidones of the formula (I) wherein all symbols are as defined earher, which comprises reacting a compound of the formula (la)
where R represent (C1-C3) alkyl group, X, R^ and R^ are as defined above, with a compound of the formula (lb)


wherein all symbols are as defined above, to produce a compound of formula {!).
The reaction of compound of formula (la) with compound of formula (lb) may be carried out using appropriate solvents like toluene, xylene, tetrahydrofuran, dioxane, chloroform, dichloromethane, dichloroethane, o-dichlorobenzene, acetone, ethyl acetate, acetonitrile, N,N-dimethylformamide, dimethylsulfoxide, pyridine, ethanol, methanol, isopropylalcohol, tert-butylalchol, acetic acid, propionic acid etc, a mixture thereof or the like or by neat reactions. The condensation reaction may be carried out under acidic conditions using mineral or organic acids, or basic conditions viz. carbonates, bicarbonates, hydrides, hydroxides, alkyls and alkoxides of alkali metals and alkaline earth metals. The reaction may be carried out by using phase transfer catalysts viz. triethylbenzylammonium chloride, tetrabutylammonium bromide, tetrabutylammonium hydrogensulphate, tricaprylylmethylammonium chloride (aliquat 336) and the like. The reaction is usually carried out under cooling to refluxing conditions. The final product purified by using chromatographic techniques or by recrystallization. The reaction may be carried out for period in the range of 2 to 20 h.
According to another embodiment of the present invention, there is provided a process for the preparation of novel pyrimidones of the formula (I) wherein all symbols arc as defined earlier, which comprises reacting a compound of the formula (Ic)


where R represent (C1-C3) alkyl group and all other symbols are as defined above, with a compound of the formula (Id)

wherein all symbols are as defined above, to produce a compound of formula (I).
The reaction of compound of formula (Ic) with compound of formula (Id) may be carried out using appropriate solvents like toluene, xylene, tetrahydrofuran, dioxane, chloroform, dichloromethane, dichloroethane, o-dichlorobenzene, acetone, ethyl acetate, acetonitrile, N,N-dimethylformamide, dimethylsulfoxide, pyridine, ethanol, methanol, isopropylalcohol, tert-butylalcohol, acetic acid, propionic acid etc, a mixture thereof or the like or by neat reactions. The condensation reaction may he carried out under acidic conditions using mineral or organic acids, or basic conditions viz. carbonates, bicarbonates, hydrides, hydroxides, alkyls and alkoxides of alkali metals and alkaline earth metals. The reaction may be carried out by using phase trarsfer catalysts viz. triethylbenzylammonium chloride, tetrabutylammonium bromide, tetrabutylammonium hydrogensulphate, tricaprylylmethylammonium chloride (aliquat 336) and the like. The reaction is usually carried out under cooling to refluxing conditions. The final product purified by using chromatographic techniques or by recrystallization. The reaction may be carried out for period in the range of 30 min. to 10 hours.
According to yet another embodiment of the present invention there is provided a process for the conversion of novel pyrimidones of the formula (I)

wherein any of the groups R' or R^ represent SR^, wherein R' represents hydrogen, alkyl or aryl to novel pyrimidones of the formula (I) wherein any of the groups R' or R"* represent S(0)pR^, where p represents 1 or 2 and R^ represents alkyl or aryl; by using suitable oxidizing agent. The oxidizing agent may be selected from potassium peroxymonosulfate (Oxone), hydrogen peroxide, tert-butylperoxide, Jones reagent, peracid [e.g peracetic acid, perbenzoic acid, m-chloroperbenzoic acid etc], chromic acid, potassium permanganate, alkali metal periodate [e.g sodium periodate, etc], magnesium mono peroxypthalate, osmium tetroxide/N-methylmorpholine-N-oxide, sodium tungstate, and the like. The oxidation is usually carried out in a solvent which does not adversely influence the reaction such as acetic acid, dichloromethane, acetone, ethyl acetate, chloroform, water, an alcohol such as, methanol, ethanol, isopropanol and the like or mixture thereof The reaction temperature is usually carried out under cooling to refluxing conditions.
According to yet another embodiment of the present invention there is provided a process for the conversion of novel pyrimidones of the formula (I) wherein R' or R^ represent S{0)pR^, where p is 1 or 2, R^ represents alkyl or aryl may be converted to novel pyrimidones of the formula (I) wherein R' or R^ represent S(0)pR^, where p is 1 or 2, R^ represents amino by using the procedure described in the literature (Huang et.ai. Tetrahedron Lett., 39, 720i, 1994).
In yet another embodiment of the present invention, there is provided a process for the preparation of novel pyrimidones of the formula (I) wherein either of R' or R^ represent S(0)pR^, wherein R^ represents amino group and p represents an integer of 1 or 2 and all other symbols are as defined earlier, which comprises reacting compound of formula (le) wherein all symbols are as defined earlier


where either of R' or R^ represents hydrogen with chlorosulfonic acid and ammonia.
The reaction of compound of formula (le) with chlorosulfonic acid and ammonia may be carried out in the presence of solvents such as acetic acid, dichloromethane, acetone, tetrahydrofliran, dioxane, ethyl acetate, chloroform, water, an alcohol and the like or a mixture thereof or in absence of solvents. The reaction may be carried out at a temperature in the range of 0 °C to reflux temperature for period in the range of 2 to 24 h.
In yet another embodiment of the present invention, there is provided a novel intermediate of formula (lb)

their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, and their pharmaceutically acceptable salts, wherein the rings represented by A and B are selected from aryl or heteroaryl; R' and R^ are different and represent hydrogen, SR^, wherein R' represents hydrogen, alkyl or aryl, or S(0)pR*, wherein R^ represents alkyl, amino or aryl group and p represents an integer of 1 or 2; R^ and R"* may be same or different and independently represent hydrogen, halogen, hydroxyl, nitro, cyano, azido, nitroso, amino, formyl, alkyl, haloalkyl, acyl, alkoxy, monoalkyiamino, dialkylamino, acylamino, alkoxycarbonyl, alkylsulfonyl, alkylsulfmyl, alkylsulfanyl, sulfamoyl, alkoxyalkyl groups or carboxylic acids or its

derivatives; m is an integer and is in the range of 0 to 4; n is an integer and is in the rangeofO to4.
In yet another embodiment of the present invention, there is provided a process for the preparation of novel intermediate of formula (lb), which comprises, methylating the compoimd of formula {Ib-2)

The methylation of Ib-2 may be carried out by treating with methylating agent like methyliodide, dimethylsulphate and diazomethane etc., in the presence of base such as sodium hydroxide, potassium hydroxide, sodium methoxide, sodium hydride, potassium t-butoxide, calcium hydroxide, magnesium hydroxide and the like, in solvents like ether, tetrahydroftiran, methanol, t-butanol, dioxane, isopropanol, ethanol, water etc.
In yet another embodiment of the present invention, there is provided a process for the preparation of novel intermediate of formula (Ib-2), which comprises, reacting compound of formula (Ib-3)

where R] and Ri all are as defined above with compound of formula (Ib-4)

where all symbols are as defined above.
The reaction of compound of formula (Ib-3) with compound of formula (Ib-4) may be carried out in solvents like toluene, xylene, tetrahydrofuran, dioxane.

chloroform, dichloromethane, dichloroethane, o-dichlorobenzene, acetone, ethyl acetate, acetonitrile, N,N-dimethylfDrmamide, dimethylsulfoxide, pyridine, ethanol, methanol, isopropylalcohol, tert-butylalcohol, acetic acid, propionic acid etc, a mixture thereof or the like or by neat reactions. The reaction may be carried out at a temperature in the range of 0 to 200 °C for period in the range of 30 min. to 5 hours.
In yet another embodiment of the present invention, there is provided a novel intermediate of formula (Id)

their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, and their pharraaceutically acceptable salts, wherein the rings represented by A and B are selected from aryl or heteroaryl; R' and R^ are different and represent hydrogen, SR', wherein R^ represents hydrogen, alkyl or aryl, or S(0)pR*, wherein R* represents alkyl, amino or aryl group and p represents an integer of 1 or 2; R^ and R* may be same or different and independently represent hydrogen, halogen, hydroxyl, nitro, cyano, azido, nitroso, amino, formyl, alkyl, haloalkyl, acyl, alkoxy, monoalkylamino, dialkylamino, acylamino, alkoxycarbonyl, alkylsulfonyl, alkylsulfmyl, alkylsulfanyl, sulfamoyl, alkoxyalkyl groups or carboxylic acids or its derivatives; m is an integer and is in the range of 0 to 4; n is an integer and is in the rangeof0to4.

In yet another embodiment of the present invention, there is provided a process for the preparation of novel intermediate of formula (Id), which comprises, reacting compound of formula (Ib-3)

where all symbols are as defined above.
The reaction of compound of formula (Ib-3) with compound of formula (Id-1) may be carried out in the presence of catalysts like aluminium chloride, triethyl aluminium, sodium hydride, sodium methoxide, butyl lithium, lithium diisopropylamine, sodium bis trimethyl silylamide, lithium bis trimethyl silylamide, using solvents like toluene, xylene, tetrahydroftiran, dioxane, chloroform, dichloromethane, dichloroethane, o-dichlorobenzene, acetone, ethyl acetate, acetonitrile, N,N-dimethylformamide, dimethylsulfoxide, ethanol, methanol, isopropylalcohol, tert-butylalchol, acetic acid, propionic acid etc, a mixture thereof or the like or by neat reactions. The reaction may be carried out at a temperature in the range of 0 to 200 "^C for period in the range of 30 min. to 10 hours.
It is appreciated that in any of the above-mentioned reactions, any reactive group in the substrate molecule may be protected according to conventional chemical practice. Suitable protecting groups in any of the above-mentioned reactions are those used conventionally in the art. The methods of formation and removal of such

protecting groups are those conventional methods appropriate to the molecule being protected.
The pharmaceutically acceptable salts are prepared by reacting the compoimd of formula (I) with 1 to 4 equivalents of a base such as sodium hydroxide, sodium methoxide, sodium hydride, potassium t-butoxide, calcium hydroxide, magnesium hydroxide and the like, in solvents like ether, tetrahydrofliran, methanol, t-butanol, dioxane, isopropanol, ethanol etc. Mixture of solvents may be used. Organic bases such as diethanolamine, a-phenylethylamine, benzylamine, piperidine, raorpholine, pyridine, hydroxyethylpyrrolidine, hydroxyethylpiperidine, choline, guanidine and the like, ammonium or substituted ammonium salts, aluminum salts. Amino acid such as glycine, alanine, cystine, cysteine, lysine, arginine, phenylalanine etc may be used for the preparation of amino acid salts. Alternatively, acid addition salts wherever applicable are prepared by treatment with acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, p-toluenesulphonic acid, methanesulfonic acid, acetic acid, citric acid, maleic acid, salicylic acid, hydroxynaphthoic acid, ascorbic acid, palmitic acid, succinic acid, benzoic acid, benzenesulfonic acid, tartaric acid and in solvents like ethyl acetate, ether, alcohols, acetone, tetrahydrofuran, dioxane etc. Mixture of solvents may also be used.
The stereoisomers of the compounds forming part of this invention may be prepared by using reactants in thetr single enantiomeric form in the process wherever possible or by conducting the reaction in the presence of reagents or catalysts in their single enantiomer form or by resolving the mixture of stereoisomers by conventional methods. Some of the preferred methods include use of microbial resolution, resolving the diastereomeric salts formed with chiral acids such as mandelic acid, camphorsulfonic acid, tartaric acid, lactic acid, and the like wherever applicable or chiral bases such as brucine, cinchona alkaloids and their derivatives and the like.

Commonly used methods are compiled by Jaques et al in "Enantiomers, Racemates and Resolution" (Wiley Interscience, 1981). More specifically the compound of formula (I) may be converted to a 1:1 mixture of diastereomeric amides by treating with chiral amines, aminoacids, aminoalcohols derived from aminoacids; conventional reaction conditions may be employed to convert acid into an amide; the diastereomers may be separated either by fractional crystallization or chromatography and the stereoisomers of compound of formula (I) may be prepared by hydrolysing the pure diastereomeric amide.
Various polymorphs of compound of general formula (I) forming part of this invention may be prepared by crystallization of compound of formula (I) under different conditions. For example, using different solvents coinmohly used or their mixtures for recrystallization; crystallizations at different temperatures; various modes of cooling, ranging from very fast to very slow cooling during crystallizations. Polymorphs may also be obtained by heating or melting the compound followed by gradual or fast cooling. The presence of polymorphs may be determined by solid probe NMR spectroscopy, ir spectroscopy, differential scanning calorimetry, powder X-ray diifraction or such other techniques.
Pharmaceutically acceptable solvates of the compounds of formula (I) forming part of this invention may be prepared by conventional methods such as dissolving the compounds of formula (I) in solvents such as water, methanol, ethanol, mixture of solvents such as acetone:water, dioxane: water, N,N-dimethyiformamide: water and the like, preferably water and recrystallizing by using different crystallization techniques.
The present invention provides a pharmaceutical composition, containing the compounds of the general formula (I) as defined above, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable hydrates and solvates in combination with the usual

pharmaceutically employed carriers, diluents and the like, useful for the treatment of inflammation, arthritis, pain, fever, psoriasis, allergic diseases, asthma, inflammatory bowel syndrome, gastro-intestinal ulcers, cardiovascular disorders including ischemic heart disease, atherosclerosis, cancer, ischemic-induced cell damage, particulariy brain damage caused by stroke, other pathological disorders associated with free radicals.
The pharmaceutical composition may be in the forms normally employed, such as tablets, capsules, powders, syrups, solutions, aerosols, suspensions and the like, may contain flavoring agents, sweeteners etc. in suitable solid or liquid carriers or diluents, or in suitable sterile media to form injectable solutions or suspensions. Such compositions typically contain from 1 to 20 %, preferably 1 to 10 % by weight of active compound, the remainder of the composition being pharmaceutically acceptable carriers, diluents or solvents.
The present invention is provided by the examples given below, which are provided by way of illustration only and should not be considered to limit the scope of the invention.
Preparation 1 4-Chloro-N-|4-(inethylthio)phenyl]benzenecarboxiniidaiiii(le

Finely powdered anhydrous aluminium chloride (0.83g, 6mmol) was added to a stirred mixture of 4-chlorobenzonitrile {0.6875g, 5mmol) and 4-methylthioaniline (0.695g, 5mmol) over a period of 30 min. The reaction mixture was heated at 180 -190 °C for 3 hours with stirring and allowed to cool to 50 °C. The resultant mixture

was triturated with ethyl acetate and basified with sodium hydroxide (20%) solution. The ethyl acetate layer was washed with water, dried over anhydrous sodium sulphate and concentrated to give the crude product, which was purified by column chromatography to yield the title compound (0.6g, 43.4%, purity 98.8% by HPLC), mp 148 - 150 °C. 'H-NMR (CDCI3): 6 2.48 (s, 3H), 6.90-6.97(m, 2H), 7.11-7.41(m, 4H), 7.74 (bs, 2H). MS m/z: 277.0 (M^)


The title compound was prepared from benzonitrile (3.705g, 35.97mmol) and 4-melhylthioaniline (5.0g, 35.97mmol) by following the procedure described in preparation 1, (3.66g, 42.1%, purity 99.8% by HPLC), mp 129 - 131 °C. 'H-NMR (CDCI3): 6 2.49 (s, 3H), 4.84 (bs, 2H), 6.94-6.96 {d, 2H), 7.26-7.31 (m, 2H), 7.45-7.49 (m, 3H), 7.87-7.88 (d, 2H). MS m/z: 243.2 (M"")



A solution of oxone (18.42g, 0.03mol) in water (70ml) was added dropwise to the vigorous stirred solution of 4-methylthiobenzonitrile (1.49g, O.Olmol) in methanol (50ml) at 20 °C and stirring was continued for three hours. The reaction mixture was diluted with water (50ml) and extracted with ethyl acetate. The ethyl acetate extract


The title compound was obtained from 4-methylsulphonylbenzonitrile (2.00g, 1 Immol) (obtained according to the procedure described in preparation 7) and 4-methylaniUne (1.18g, 1 Immol) according to the procedure described in preparation 1, (1.25g, 39.3%, purity 90.7% by HPLC), mp 187 - 189 °C. 'H-NMR (CDCis): 5 2.34 (s, 3H), 3.07(s, 3H), 4.92 (bs, 2H, DjO exchangeable), 6.87 - 6.89 (d, 2H), 7.18-7.20 (d, 2H), 8.01- 8.03 (d, 2H), 8.08 - 8.1 (d, 2H). MS m/z: 289.1(M^.



To a solution of 3,4-dimethylaniline (lOg, 83minol) in THF (10ml), lithium bis(trimethylsilyl)amide {20% in THF, 93ml, 99mmol) was added under stirring in nitrogen blanket for a period of 20 minutes followed by 4-methylthiobenzonitrile (}2.31g, 83mmoI) over a period of 10 min. After 1 hour the reaction mixture was poured over ammonium chloride solution {30%, 100ml). The resultant mixture was extracted with ethyl acetate and washed with water, dried over anhydrous sodium sulphate. The ethyl acetate extract was concentrated to yield the title compound {19g, yield 85.1%, mp 111- 113 °C, purity 99.1% by HPLC). 'H-NMR (CDCI3): 6 2.23-2.24 {d, 6H), 2.51 (s, 3H), 4.81 (bs, 2H, D2O exchangeable), 6.70 - 6.72 {m, IH), 6.77 (s, IH), 7.08- 7.1 {d, IH), 7.25 - 7.27 (d, 2H), 7.76 - 7.78 (d, 2H). MS m/z: 271.3 (M^).


The title compound was prepared from 4-methylsulfonylbenzonitrile {5.0g, 28mmol) and 3,4-dimethylaniline (3.36g, 28mmol) by following the procedure described in preparation 1 (3.75g, yield 45 %, purity 97.1% by HPLC). 'H-NMR {CDCI3): 5 2.25 - 2.26 (d, 6H), 3.07 (s, 3H), 4.91 (bs, 2H, D2O exchangeable), 6.71 - 6.73 (m, IH),


The title compound was prepared from 4-methylthiobenzonitrile (1.23g, 8.2mmol) and 4-ethylaniline (Ig, 8.2nunol) by following the procedure described in preparation 10 (l.Slg, yield 81.1%, mp 156 - 158 °C, purity 98.6% by HPLC). 'H-NMR(CDCI3): 6 1.22 - 1.26 (t, 3H), 2.51 (s, 3H), 2.60 - 2.66 (q, 2H), 4.70 (bs, 2H, DjO


The title compound was prepared from 4-methylthiobenzonitrile (12.1 Ig, Slmmol) and 4-methoxyaniline {lOg, Slmmol) by following the procedure described in preparation 10 (17g, yield 76.84%, mp 166 - 168 'C, purity 97.25% by HPLC). 'H-NMR (CDCI3): 6 2.51 (s, 3H), 3.80 (s, 3H), 4.80 (bs, 2H, D2O exchangeable), 6.91 (s, 4H), 7.26 - 7.29 (m, 2H), 7.78 - 7.8 (d, 2H). IR (KBr) cm-': 3461, 3320, 2949, 2922, 2829, 1615. MS m/z: 273.1 (M*).


The title compound was prepared from 4-methylthiobenzonitriIe (11.7g, 78mmol) and 4-chloroaniline (lOg, 78mmol) by following the procedure described in preparation 10 (18.06g, yield 83.26%, purity 98.9% by HPLC). MS m/z: 277.1 / 278.7 (M^).


The title compound was prepared from 4-methylbenzonitriIe (8.42g, 72mmol) and 4-methylthioaniline (lOg, 72mmol) by following the procedure described in preparation 10 {12.25g, yield 66.5%, purity 99.8% by HPLC). 'H-NMR (CDCI3): 5 2.40 (s, 3H), 2.48 (s, 3H), 4.82 (bs, 2H, DjO exchangeable), 6.92 - 6.94 (d, 2H), 7.22 - 7.29 (m, 4H), 7.74 - 7.75 (d, 2H). MS m/z: 257.1 (WC).


The title compound was prepared from 4-methylthiobenzonitrile (Ig, 6.7mmol) and 4-tert-butylaniline (Ig, 6.7mmol) by folJowing the procedure described in preparation 10 (1.24g, yield 62.13%, purity 98.67% by HPLC). 'H-NMR (CDCI3): 6 1.32 (s, 9H), 2.51 (s, 3H), 4.81 (bs, 2H, D2O exchangeable), 6.90 - 6.92 (d, 2H), 7.26 - 7.29 (ra, 2H), 7.35 - 7.37 (m, 2H), 7.78 - 7.8 (d, 2H). MS m/z: 299.4 (M"").


The title compound was prepared from 4-methylthiobenzonitrile (Ig, 6.7mmol) and 4-n-butylaniline (Ig, 6.7mmol) by following the procedure described in preparation 10 (1.27g, yield 63.66%). 'H-NMR (CDCI3): 5 0.91 - 0.95 (t, 3H), 1.33 - 1.39 (m, 2H), 1.56 - 1.63 (m, 2H), 2.52 (s, 3H), 2.56 - 2,6 (m, 2H), 4.8 (bs, 2H, D2O exchangeable), 6.88 - 6.9 (d, 2H), 7.15 - 7.17 (d, 2H). 7.27 - 7.29 (m, 2H), 7.79 - 7.81 (d, 2H). MS m/z: 299.3 (M^).


The title compound was prepared from 3-cyanopyridine (0.94g, 9mmol) and 4-fluoroaniline (Ig, 9mmol) by following the procedure described in preparation 10 (1.5g, yield 76.9%, purity 97.95% by HPLC). 'H-NMR (CDCI3): 6 4.93 (bs, 2H, DzO exchangeable), 6.92-6.96 (m, 2H), 7.05 - 7.07 (m, 2H), 7.38 - 7.41 (m, IH), 8.22 (s, IH), 8.71 - 8.72 (d, IH), 9.06 (s, IH). MS m/z; 216.3 (M^.

The title compound was prepared from 4-cyanopyridine (1.5g, 14mmol) and 4-methylthioaniline (2g, 14mmo\) by following the procedure described in preparation 10 (1.87g, yield 53.6%).


The title compound was prepared from 2-cyanopyridine (1.5g, 14mmol) and 4-methylthioaniline (2g, Hmmol) by following the procedure described in preparation 10 [3.0g, yield 85.71%(crude basis)].
Preparation 31 N-(4-Methoxypheny0pyridine-2-carboximidamide


The title compound was prepared from 2-cyanopyridine (8.6g, 83mmol) and 3,4-dimethylaniline (10g, 83mmol) by following the procedure described in preparation 10 (13.2g, yield 71.2%, mp 105 - 107 °C, purity 99.9% by HPLC). 'H-NMR (CDC13): 5 2.24 - 2.25 (d, 6H), 5.75 - 6 (bs, 2H, D20 exchangeable), 6.75 - 6.81 (m, 2H), 7.11 - 7.13 (d, 1H), 7.36 - 7.39 (m, 1H), 7.78 - 7.82 (m, 1H) 8.39 - 8.41 (d, 1H), 8.55 -8.57 (m, 1H). IR (KBr) cm'1: 3445, 3303, 1645, 1625. MS m/z: 227 (M*)-

V

The title compound was prepared from 2-cyanopyridine (9.7g, 93mmol) and 4-methylaniline (lOg, 93mmol) by following the procedure described in preparation 10 (8.2g, yield 41.6%). MS m/z: 212.1(M+).
Preparation 35 N-(4-Ethoxyphenyl)pyridine-4-carboximidamide


The title compound was prepared from 4-cyanopyridine (7.58g, 72mmol) and 4-ethoxyaniline (10g, 72mmol) by following the procedure described in preparation 10 (15.70g, yield 89.3%, purity 99.4% by HPLC). MS m/z: 242.3 (M+).



The title compound was prepared from 3-cyanopyridine (8.5g, 83mmol) and 4-ethylaniline (lOg, 83mmol) by following the procedure described in preparation 10 (15.8g, yield 84.9%, mp 134 - 136 "C, purity 99.8% by HPLC). 'H-NMR (CDC13): 5 1.22 - 1.26 (t, 3H), 2.60 - 2.65 (q, 2H), 5.09 (bs, 2H, D20 exchangeable), 6.88 - 6.89 (d, 2H), 7.18 - 7.19 (d, 2H), 7.32 - 7.35 (m, 1H), 8.18 - 8.20 (d, 1H), 8.64 - 8.65 (d, 1H), 9.03 (s, 1H). IR (KBr) cm-1: 3302, 3108, 2965, 2928, 2844, 1655. MS m/z: 227.1 (M+).


The title compound was prepared from 3-cyanopyridine (8.5g, 83mmol) and 4-methoxyaniline (lOg, 83mmoI) by following the procedure described in preparation 10 (11.6g, yield 62.82%, mp 137 - 139 °C, purity 97.2% by HPLC). 'H-NMR (CDC13): 6 3.81 (s, 3H), 4.94 (bs, 2Hf D20 exchangeable), 6.93 (s, 4H), 7.37 - 7.4 (d, 1H), 8.22 - 8.24 (d, 1H), 8.70 - 8.71 (d, 1H), 9.0 (s, 1H). IR (KBr) cm"1: 3281, 3085, 3001, 2960,2937, 1660. MS m/z: 228.2 (M+).


A mixture of ethyl 2-cyano-3,3-dimethyIthioacrylate (1.345g, 6.2mmol) and 4-chloro-N-[4-(methylthio)phenyl]benzenecarboximidamide (1.7g, 6.2mmol) (obtained according to the procedure described in preparation 1) was heated at 110 -120 °C for 2 hours. The gummy mass thus obtained was purified by column chromatography to give the title compound (l.lg, yield 44.4%, purity 94.6% by HPLC), mp 206-207 °C.[H-NMR (CDC13): 5 2.47 (s, 3H), 2.66 (s, 3H), 6.99 -7.01 (d, 2H), 7.18-7.30 (m, 6H). IR (KBr) cm"1:2218(-CN), 1672 (-C=0). MS m/z: 400.l(ht).


The title compound was prepared from ethyl 2-cyano-3,3-dimethylthioacrylate (1.345g, 6.2mmol) and N-[4-(methylthio)phenyl]benzenecarboximidamide (1.50g, 6.2mmol) (obtained in preparation 3) by following the procedure described in example 1, <1.28g, yield 56.6%, purity 98.8% by HPLC), mp 204 - 205 °C. 'H-NMR






The title compound was prepared from ethyl 2-cyano-3,3-dimethylthioacrylate
(0.378g, ].74mmol) and N-(4-methylphenyl)-4-
(methylsulfonyl)benzenecarboximidamide (0.5g, 1,74mmol) (obtained in preparation 8) according to the procedure described in example 1, (0.43g, 59.6%, purity 99.1% by HPLC), mp 242 - 244 °C. 'H-NMR (CDC13): 5 2.34 (s, 3H), 2.65 (s, 3H), 3.04 (s, 3H), 6.95 - 6.97 (d, 2H), 7.15 - 7.17 (d, 2H), 7.51 - 7.54 (d, 2H), 7.82 -7.84 (d, 2H). IR (KBr) cm-': 2217 (-CN), 1696 (-CO). MS m/z: 412 (M*).
Example 8
Synthesis of 5-carboxy-2- [(4-methylthio)pheny 1] -4-(methy lthio)-l-(4-
methylphenyl)-6-oxo-l,6-dihydropyrimidine

A mixture of 5-cyano-l-(4-methyJphenyl)-4-(methy]thio)-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine (2.5g, 6.59mmol) (obtained according to the procedure described in example 6) and potassium hydroxide (40%, 25ml) solution was refluxed for 2 hours. The reaction mixture was poured onto ice-water, neutralised with dilute hydrochloric acid and filtered. The solid thus obtained was washed with water and dried to yield title compound (2.12g, 80.8%, purity 91.6% by HPLC), mp 173 - 175 °C. 'H-NMR (CDC13): 5 2.34 (s, 3H), 2.53 (s, 3H), 2.69 (s, 3H), 7.16 - 7.18 (d, 2H),

7.26 - 7.37 (m, 4H), 7.92 - 7.94 (d, 2H), 14.0 (s, 1H, D20 exchangeable). IR (KBr) cm"1: 331 l(-COOH), 1702(-O0). MS m/z: 398.5 (M+).
Example 9
Synthesis of 5-cyano-l-(4-isopropylphenyl)-4-(methy}tblo)-2-{4-
(methylthio)phenyl]-6-oxo-l,6-dihydropyrimidine

A mixture of ethyl 2-cyano-3,3-dimethylthioacrylate (3.8g, 17.6mmol) and N-(4-isopropylphenyl)-4-(methylthio)benzenecarboxirnidamide (5g, 17mmol) (obtained according to preparation 9) was heated at 110 -120 °C for 3 hours. The crude solid was triturated with diethyl ether and filtered to give the title compound (1.22g, yield 17.1%, mp 180-181 °Ct purity 99.29% by HPLC). 'H-NMR (CDC13): 5 1.21-1.23 (d, 6H), 2.44 (s, 3H), 2.67 250 °C, purity 99.8% by HPLC). 'H-NMR (CDC13): 5 2.19 (s, 3H)b 2.23 (s, 3H), 2.67 (s, 3H), 6.78 - 6.8 (d, 1H), 6.92 -6.93 (d, 1H), 7.09-7.11 (d, 1H), 7.18 - 7.21 (d, 1H), 7.6 - 7.62 (d, 1H), 8.56 - 8.64 (dd, 2H). IR (KBr) cm"1: 3427, 2930,2215 (-CN), 1688 (-C=0). MS m/z: 349.1 (NT).


The title compound was prepared from ethyl 2-cyano-3,3-dimethylthioacrylate (1.5g, 6.7mmol) and N-(4-methoxyphenyl)pyridine-3-carboxirnidamide (1.5g, 6.7mmol) (obtained according to preparation 40) according to the procedure described in example 9 (1.4g, yield 60.6%, mp 230 - 233 °C, purity 99.75% by HPLC). 'H-NMR (CDC13): 5 2.67 (s, 3H), 3.79 (s, 3H), 6.85 - 6.88 (d, 2H), 7.01 - 7.04 (d, 2H), 7.20 -7.21 (d, 1H), 7.56 - 7.58 (d, 1H), 8.57 - 8.58 (d, 2H). IR (KBr) cm-1: 3054, 3009, 2836, 2213 (-CN), 1691 (-00). MS m/z: 351.2 (M+).


Example 42
Synthesis of ethyl H4-fluorophenyl)-4-(methylthio)-2-|4-(methyIthio)phenylJ-6-
oxo-l,6-dihydropyrimidine-5-carboxylate

The title compound was prepared from diethyl [bis(methylthio)methylene]malonate (0.88g, 3.3mmol) and N-(4-fluorophenyl)-4-(methylthio)benzenecarboximidamide (0.87g, 3.3mmol) (prepared according to the procedure described in preparation 5) by following the procedure described in example 41 (0.22g, yield 15.7%, mp 151 - 155 °C, purity 99.72% by HPLC). 'H-NMR (CDC13): 5 1.37 - 1.40 (t, 3H), 2.45 (s, 3H), 2.55 (s, 3H), 4.38 - 4.43 (q, 2H), 7.02 - 7.07 (m, 4H), 7.11 - 7.14 (m, 2H), 7.22 -7.26 (m, 2H). IR (KBr) cm'1: 3360, 3072, 2978, 2924, 1694 (-C=0). MS m/z: 431.2 (M+).
Example 43
Synthesis of ethyl 2-(4-fluorophenyl)-4-(methylthio)-l-[4-(methylthio)phenyl]-6-
oxo-l,6-dihydropyrimidine-5-carboxylate

The title compound was prepared from diethyl [bis(methylthio)methylene]malonate (5.3g, 20mmol) and N-(4-methythiophenyl)-4-(fluoro)benzenecarboximidamide

(5.2g, 20mmol) {prepared according to the procedure described in preparation 2) by following the procedure described in example 41 (0.25g, yield 2.9%, mp 166 -169°C, purity 96.84% by HPLC). 'H-NMR (CDC13): 5 1.36 - 1.4 (t, 3H), 2.45 (s, 3H), 2.55 (s, 3H), 4.38 - 4.43 (q, 2H), 6.91 - 6.96 (m, 2H), 7.01 - 7.03 (d, 2H), 7.16 - 7.18 (d, 2H), 7.33 - 7.37 (m, 2H). IR (KBr) cm"1: 3447, 3069, 2989, 2900, 1733, 1666.MSm/z:431.2.0(M+).


Example 45
Synthesis of 5-carboxamido-l-(4-methylphenyl)-2-[4^methyIsulfonyI)phenyl]-6-
oxo-4-piperazin-l-y 1-1,6-dihydropyrimidine

The title compound was prepared from 5-carboxamido-l-(4-methylphenyl)-4-(methylsulfonyl)-2-[4-(methylsulfonyl)phenyl]-6-oxo-l,6-dihydropyrimidine (0.5g, l.lmmol) (obtained in example 44) by refiuxing with piperazine ( O.lg, 1.2mmol) in ethanol (20ml) for 2hrs. The resultant reaction mixture was filtered to yield the compound (0.4g, yield 75.09%, mp 269 - 275 °C, purity 94.87% by HPLC). 'H-NMR (CDC13): 5 2.33 (s, 3H), 3.03 (s, 3H), 3.84 (bs, 8H), 5.55 (s, 1H, D20 exchangeable), 6.99 - 7.02 (d, 2H), 7.14 - 7.16 (d, 2H), 7.51 - 7.53 (d, 2H), 7.80 -7.82 (d, 2H), 8.73 (s, 1H, D20 exchangeable). IR (KBr) cm-1: 3399, 2924, 1645 (-OO). MS m/z: 468.2 (M4).
Example 46
Synthesis of 5-carboxamido-4-(methylamino)-l-(4-methylphenyl)-2-[4-
(methylsulfonyl)pheny I]-6-oxo-l,6-dihydropyrimidine

The title compound was prepared from 5-carboxamido-l-(4-methylphenyl)-4-(methylsulfonyl)-2-[4-(methylsulfonyl)phenyl]-6-oxo-l, 6-dihydropyrimidine (0.3g,

0.7mmol) (obtained in example 44) by refluxing with methylamine (O.lg, 3.3mmol) in ethanol (15ml) according to the procedure described in example 45 (0.25, yield 93.3%, mp >300 °C, purity 98.59% by HPLC). 'H-NMR (CDC13): 6 2.32 (s, 3H), 3.02 (s, 3H), 3.13 - 3.14 (d, 3H), 5.43 (s, 1H, D20 exchangeable), 6.96 - 6.98 (d, 2H), 7.12 - 7.14 (d, 2H), 7.52 - 7.54 (d, 2H), 7.79 - 7.81 (d, 2H), 8.75 (s, 1H, D20 exchangeable). IR (KBr) cm"1: 3320, 3155, 3020, 2926, 1656, 1607(-C=O). MS m/z: 413.3 (M+).

The title compound was prepared from 5-carboxamido-l-(4-methylphenyl)-4-(methylsulfonyl)-2-[4-(methylsulfonyl)phenyl]-6-oxo-l,6-dihydropyrimidine (0-5g, l.lmmol) (obtained in example 44) by refluxing with morpholine (O.lg, 1.2mmol) in ethanol (15ml) according to the procedure described in example 45 (0.36, yield 72%, mp 226 - 228 °C, purity 98.86% by HPLC). lH-NMR (CDC13): 5 2.33 (s, 3H), 3.02 (s, 3H), 3.79 - 3.82 (m, 8H), 5.52 (s, 1H, D20 exchangeable), 6.98 - 7.0 (d, 2H), 7.13 - 7.15 (d, 2H), 7.49 - 7.51 (d, 2H), 7.79 - 7.81 (d, 2H), 8.72 (s, 1H, D20 exchangeable). IR (KBr) cm"1: 3440, 3319, 2965,2927, 2857, 1658 (-00). MS m/z: 469.2 (M+).


The title compound was prepared from 5-cyano-2-(4-fluorophenyl)-l-[4-(methylthio)phenyl)-4-(methylthio)-6-oxo-l,6-dihydropyrimidine (2.5g, 6.5mmol, prepared according to the procedure disclosed in example 2) according to the procedure described in example 44 (1.5g, yield 49.2%, mp 237 - 241 °C, purity 93.95% by HPLC). 'H-NMR (DMSO): 5 3.20 (s, 3H), 3.27 (s, 3H), 7.14 - 7.19 (m, 2H), 7.42 - 7.46 (m, 2H), 7.61 - 7.63 (m, 2H), 7.75 (s, 2H, D20 exchangeable), 7.94 - 7.97 (m, 2H). IR (KBr) cm'1: 3416, 3012,2923, 1681 (-C=0). MS m/z: 466.1 (M+).

The title compound was prepared from 5-carboxamido-2-(4-fluorophenyl)-4-(methylsulfonyl)-l-[4-(methylsulfonyl)phenyl]-6-oxo-l,6-dihydropyrimidine (0.75g, 1.6mmol) (obtained in example 48) by refluxing with methylamine (lg, 13mmol) in

ethanol (15ml) according to the procedure described in example 45 (0.35, yield 52.3%, mp >300 °C, purity 96.54% by HPLC). 'H-NMR (DMSO): 6 3.04 - 3.05 (d, 3H), 3.21 (s, 3H), 7.10 - 7.14 (m, 2H), 7.33 - 7.34 (d, 1H, D20 exchangeable), 7.41 - 7.45 (m, 2H), 7.58 - 7.60 (d, 2H), 7.85 - 7.87 (d, 2H), 8.91 - 8.92 (d, 1H, D20 exchangeable), 10.58 - 10.59 (d, 1H, D20 exchangeable). IR (KBr) cm*1: 3442, 3368, 3296, 3107, 3009, 2916, 1662 (-0=0). MS m/z: 417.2 (M+).



The title compound was prepared from 5-cyano-2-(4-fluorophenyl)-l-[4-(methylthio)phenyl)-4-(methylthio)-6-oxo-l,6-dihydropyrimidine (5g, 13mmol,

prepared according to the procedure disclosed in example 2) in acetic acid (20ml) and then added hydrogen peroxide (20ml) under stirring. The reaction was refluxed at S0°C for 3hrs and filtered the solid and followed according to the procedure described in example 44 (1.2g, yield 24%, mp >285 °C, purity 93.63% by HPLC). 'H-NMR (DMSO): 5 3.21 (s, 3H), 3.38 (bs, 1H, D20 exchangeable), 7.18 - 7.23 (m, 2H), 7.48 - 7.52 (m, 2H), 7.60 - 7.62 (d, 2H), 7.88 - 7.9 (d, 2H). IR (KBr) cm'1: 3428, 3283, 2922, 2211 (-CN), 1701, 1668, 1606 (-C=0). MS m/z: 386.1 (M+).


Example 54
Synthesis of 5-cyano-4-(methylamino)-l-(4-methylphenyl)-2-[4-
(methyIthio)phenyl]-6-oxo-l,6-dihydropyrimidine

A suspension of 5-cyano-1 -(4-methylphenyl)-4-(methylthio)-2-[4-
(methylthio)phenylj-6-oxo-l,6-dihydropyrimidine (2g, 5.3mmol) (prepared according to the procedure disclosed in example 6) in ethanol (20ml) with methylamine (0.33g, 10.6mmol) was refluxed for 2hr. Then the reaction mass poured on to ice and the resulted solid filtered, washed thoroughly with water. The resulted solid purified by column chromatography using ethyl acetate and hexane mixture as eluent to yield title compound (0.55g, yield 25.5%, mp 268 - 271 °C, purity 97.34% by IIPLC). 'H-NMR (CDC13): S 2.32 (s, 3H), 2.43 (s, 3H), 2.95 (d, 3H), 5.8 (s, 1H, D20 exchangeable), 6.95 - 6.97 (d, 3H), 7.02 - 7.04 (d, 1H), 7.11 - 7.13 (d, 1H), 7.22 - 7.26 (m, 3H). IR (KBr) cm-1: 3294, 2919, 2205 (-CN), 1666 (-C=0). MS m/z: 363.1 (M+).
Example 55
Synthesis of 5-cyano-l-(3,4-dimethylphenyl)-4-(methylamino)-2-[4-
(methy lthio)phenyl] -6-oxo-l ,6-dihy dropy rimidin e


A suspension of 5-cyano-l-(3,4-dimethylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-l,6-dmydropyrimidme (lg, 2.5mmol) (prepared according to example 10) in ethanol (10ml) with methylamine (0.16g, 5mmol) was refluxed for 3hr. Then the reaction mass poured on to ice and the resulted solid filtered, washed thoroughly with water. The solid thus obtained was purified by column chromatography using ethyl acetate and hexane mixture as eluent to yield title compound (0.36g, yield 38%, mp 199 - 205 °C, purity 98.72% by HPLC). 'H-NMR (CDC13): 6 2.19 (s, 3H), 2.22 (s, 3H), 2.44 (s, 3H), 3.17 - 3.18 (d, 3H), 5.73 (s, 1H, D20 exchangeable) 6.75 - 6.77 (d, 2H), 6.90 (s, 1H), 7.02 - 7.06 (m, 3H), 7.24 -7.26 (d, 1H). IR (KBr) cm-1: 3280, 2920, 2207 (-CN), 1661 (-C=0). MS m/z: 377.2 (M+).
Example 56
Synthesis of 5-cyano-2-(4-fluorophenyl)-4-(methylamino)-l-[4-
(methylthio)phenyll-6-oxo-l,6-dihydropyrimidine

The title compound was prepared from 5-cyano-2-(4-fluorophenyl)-l-[4-(methylthio)phenyl)-4-(methylthio)-6-oxo-l,6-dihydropyrimidine (lg, 2.6mmol, prepared according to the procedure disclosed in example 2) in ethanol (10ml) with

methylamine (0.16g, 5mmol) was refluxed for 2hr. Then the reaction mass poured on to ice and the resulted solid filtered, washed thoroughly with water. The solid thus obtained was purified by column chromatography using ethyl acetate and hexane mixture as eluent to yield title compound (0.4g, yield 42%, mp 219 - 222 °C purity 95.3% by HPLC). lH-NMR (CDC13): 5 2.45 (s, 3H), 3.17 - 3.18 (d, 3H), 6.0 (s, 1H, NH, D20 exchangeable), 6.91 - 6.99 (m, 4H), 7.14 - 7.16 (d, 2H), 7.31 - 7.34 (m, 2H). IR (KBr) cm'': 3279, 2981, 2931, 2208, 1736, 1651, 1604 (-00). MS m/z: 367.1 (M+).



A solution of 5-cyano-2-(4-ethoxyphenyl)-l-phenyl-4-(methylthio)-6-oxo-l,6-dihydropyrimidine (Ig, 2.7mmol) in chlorosulfonic acid (6.14g, 53mmol) and chloroform (30ml) was refluxed lhr and then poured on to ice. The chloroform layer was collected and dried over Na2S04 and concentrated under vacuo to yield title compound (0.8g, yield 62.9%). 'H-NMR (DMSO): 5 1.21 - 1.24 (t, 3H), 2.6 (s, 3H),


A solution of 5-cyano-1 -(4-methylphenyl)-4-(methylthio)-6-oxo-2-phenyl-1,6-dihydropyrimidine (5g, 15mmol) (prepared according to the procedure described for example 23) in chlorosulfonic acid (87.7g, 756mmol) was stirred at ambient temperature for 20hr. The resulted reaction mass was treated with dichloromethane (200ml) and washed with water, dried over Na2S04. The ammonia gas purged through the resulted dichloromethane layer for lhr slowly at 0-10 °C. The dichloromethane layer was again washed with water, dried over Na2S04- The solvent removed under vacuo and the solid obtained was purified by column chromatography using chloroform and methanol mixture as eluent to yield the title compound (0.25g, yield 4.0%, purity 99.7% by HPLC). 'H-NMR (DMSO): 5 2.51 (s, 3H), 2.64 (s, 3H), 7.26 - 7.41 (m, 7H), 7.49 (s, 2H, D20 exchangeable), 7.93 - 7.94 (d, 1H). MS m/z: 413 (M+).
Described below are the examples of pharmacological assays used for finding out the efficacy of the compounds of the present invention wherein their protocols and results are provided.

Rat Carrageenan Paw Edema Test
The carrageenan paw edema test is performed as described by Winter et al (Proc.Soc.Exp.Biol.Med, 111, 544, 1962). Male Wistar rats are selected and the body weights are equivalent within each group. The rats are fasted for eighteen hours with free access to water. The rats are dosed orally with the test compound suspended in vehicle containing 0.5% methylcellulose. The control rats are administered the vehicle alone. After an hour, the rats are injected with 0.1 ml of 1% Carrageenan solution in 0.9% saline into the sub-plantar surface of the right hind paw. Paw volume is measured using water plethysmograph before and after 3 hours of carrageenan injection. The average of foot swelling in drug treated animals is compared with that of control animals. Anti-inflammatory activity is expressed as the percentage inhibition of edema compared with control group [Arzneim-Forsch/Drug Res., 43(1), 1, 44-50,1993; Otterness and Bliven, Laboratory Models for Testing NSAlDs, In Non-Steroidal Anti-Inflammatory Drugs, (J. Lombardino, ed.1985)]. In order to evaluate their role on the ulcer formation, the animals are sacrificed and the stomach is taken out and flushed with 1% formalin. The stomach is opened along the greater curvature. The haemorrhagic puncta and sulci are identified microscopically and images are captured. The stomach lesions are calculated.
In vitro evaluation of Cvclooxvgenase-2 (COX-2^ inhibition activity
The compounds of this invention exhibited in vitro inhibition of COX-2. The COX-2 inhibition activities of the compounds illustrated in the examples are determined by the following method. Human Whole Blood Assay
Human whole blood provides a protein and cell rich milieu appropriate for the study of biochemical efficacy of anti-inflammatory compounds such as selective

COX-2 inhibitors. Studies have shown that normal human blood does not contain COX-2 enzyme. This is correlating with the observation that COX-2 inhibitors have no effect on prostaglandin E2 (PGE2) production in normal blood. These inhibitors are active only after incubation of human blood with lipopolysaccharide (LPS), which induces COX-2 production in the blood.
Method
Fresh blood is collected in tubes containing potassium EDTA by vein puncture from male volunteers. The subjects should have no apparent inflammatory conditions and not taken NSAIDs for atleast 7 days prior to blood collection. Blood is treated with aspirin in vitro (lOug/ml, at time zero) to inactivate COX-1, and then with LPS (lOug/ml) along with test agents or vehicle. The blood is incubated for 24 h at 37 °C, after which the tubes are centrifuged, the plasma is separated and stored at -80 °C (J.Pharmacol.Exp.Ther, 271, 1705, 1994; Proc.Natl.Acad.Sci. USA., 96, 7563, 1999). The plasma is assayed for PGE2 using Cayman ELISA kit as per the procedure outlined by the manufacturer (Cayman Chemicals, Ann Arbor, USA). Representative results of COX-2 inhibition are shown in Table I.



Tumor Necrosis Factor Aloha fTNF-ort
This assay determines the effect of test compounds on the production of TNF-a in human whole blood. TNF-cc assay is carried out as described by Armin hatzelmann and Christian Schudt (J Pharm Exp Ther 297, 261,2001). Compounds are tested for their ability to inhibit the activity of TNF-a in human whole blood. The test compounds are pre-incubated for 15 minutes at 37° C and then stimulated with Lipopolysaccharide (Salmonella abortus equi, I ng/ml) for 4 h at 37Q C in 5% C02. The levels of TNF-a are estimated using Enzyme linked Immunosorbent assay performed in a 96 well format as per the procedure of the manufacturer (Cayman Chemical, Ann Arbor, USA). Representative results of TNF-a inhibition are shown in Table II.

lntcrleukin-6 ttL-6i
This assay determines the effect of test compounds on the production of IL-6 from human whole blood. Compounds are tested for their ability to downregulate the production of IL-6 in activated whole blood. The test compounds are pre-incubated for 15 minutes at 37° C and then stimulated with Lipopolysaccharide (Salmonella abortus equi, 1 fig/ml) for 4 h at 37 ° C in 5% C02. The levels of Interleukin-6 are estimated using Enzyme linked Immunosorbent assay performed in a 96 well format as per the procedure of the manufacturer (Cayman Chemical, Ann Arbor, USA). Representative results of IL-6 inhibition are shown in Table III.



Inhibitory Action on Adjuvant Arthritis
Compounds are assayed for their activity on rat adjuvant induced arthritis according to Theisen-Popp et al., (Agents Actions, 42, 50-55,1994). Six to seven weeks old, Wistar rats are weighed, marked and assigned to groups [a negative control group in which arthritis is not induced (non-adjuvant control), a vehicle-treated arthritis control group, test substance treated arthritis group]. Adjuvant induced arthritis is induced by an injection of Mycobacterium butyricum (Difco) suspended in liquid paraffin into the sub-plantar region of the right hind paw (J.Pharmacol.Exp.Then, 284, 714, 1998). Body weight, paw volumes are measured at various days (0, 4, 14, 21) for all the groups. The test compound or vehicle is administered orally beginning post injection of adjuvant and continued for 21 days. On day 21, body weight and paw volume of both right and left hind paw, spleen, and thymus weights are determined. In addition, the radiographs of both hind paws are taken to assess the tibio-tarsal joint integrity. Hind limb below the stifle joint is removed and fixed in 1% formalin saline. At the end of the experiment, plasma samples are analysed for cytokines, interleukins and prostaglandins. The presence or absence of lesions in the stomach is also observed.

Two-factor ("treatment' and "time') Analysis of Variance with repeated measures on 'time" is applied to the percentage (%) changes for body weight and foot volumes. A post hoc Dunnett's test is conducted to compare the effect of treatments to vehicle. A one-way Analysis of Variance is applied to the thymus and spleen weights followed by the Dunnett's test to compare the effect of treatments to vehicle. Dose-response curves for percentage inhibition in foot volumes on days 4, 14 and 21 are fitted by a 4-parameter logistic function using a nonlinear Least Squares' regression. ID50 is defined as the dose corresponding to a 50% reduction from the vehicle and is derived by interpolation from the fitted 4-parameter equation.
DTP Human Tumor Cell Line Screen Methodology Of The In Vitro Cancer Screen
The three cell lines, one-dose prescreen carried out which identifies a large proportion of the compounds that would be inactive in multi-dose 60 cell line screening. The current assay utilizes a 384 well plate format and fluorescent staining technologies resulting in greater screening capacity for testing of synthetic samples. Cell Lines
The cell lines of the cancer-screening panel are grown in RPMI 1640 medium containing 5% fetal bovine serum and 2 mM L-glutamine. For a typical screening experiment, cells are inoculated into 96 well microtiter plates in 100 uL. After cell inoculation, the microtiter plates are incubated at 37° C, 5% CO2, 95% air and 100% relative humidity for 24 h prior to addition of experimental drugs. The cells are plated a densities of 5000 cells/well (MCF7), 1000 cells/well (NCI-H460), and 7500 cells/well (SF-268) to allow for varying doubling time of the cell lines. Each plate contains all three cell lines, a series of dilutions of standard agents, total kill wells and appropriate controls. Plates are incubated under standard conditions for 24 hours prior to addition of experimental compounds or extracts.

Addition of Experimental Agents (Pure Compounds)
Experimental compounds are solubilized in dimethyl sulfoxide (DMSO) at 400-times the desired maximum test concentration (maximum final DMSO concentration of 0.25%) and stored frozen. Compounds are then diluted with complete media with 0.1% gentamicin sulfate (5 JJ.1 of test sample in 100% DMSO is added to 565 ul of complete medium). 20 ul of this solution is then dispensed into test wells containing 50 ul of cell suspension to yield a test concentration of 1.00E-04M.
Two standard drugs, meaning that their activities against the cell lines are well documented, are tested against each cell line: NSC 19893 (5-FU) and NSC 123127 (Adriamycin). End point Measurement
After compound addition, plates are incubated at standard conditions for 48 hours, 10 ul/well Alamar Blue is added and the plates are incubated for an additional 4 hours. Fluorescence is measured using an excitation wavelength of 530 nm and an emission wavelength of 590 nm.
Calculation of Percent Test Cell Growth/Control (untreated) Cell Growth (T/C)
Percent growth is calculated on a plate-by-plate basis for test wells relative to control wells. Percent Growth is expressed as the ratio of fluorescence of the test well to the average fluorescence of the control wells x 100. The results are shown in table IV.

We claim:
1. Novel pyrimidones of the formula (I)

their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, and their pharmaceutically acceptable salts, wherein X represents oxygen, sulfur or NR, wherein R represents hydrogen, hydroxyl, acyl, alkyl, alkoxy, aryl, amino, hydroxylamino, alkylamino, arylamino, acylamino, alkoxyamino group; the rings represented by A and B are selected from aryl or heteroaryl; R1 and R3 may be same or different and independently represent hydrogen, SR7, S(0)pR8; R2 and R4 may be same or different and independently represent hydrogen, halogen, hydroxyl, nitro, cyano, azido, nitroso, amino, formyl, alkyl, haloalkyl, acyl, alkoxy, monoalkylamino, dialkylamino, acylamino, alkoxycarbonyl, SR7, S(0)pR8, alkoxyalkyl groups or carboxylic acids or its derivatives; R and R may be same or different and independently represent hydrogen, halogen, hydroxyl, nitro, cyano, azido, nitroso, amino, formyl, alkyl, aryl, aralkyl, haloalkyl, acyl, alkoxy, aryloxy, aralkoxy, heteroaryl, heterocyclyl, monoalkylamino, dialkylamino, acylamino, alkoxycarbonyl, SR7, S(0)pR8, alkoxyalkyl groups or COR9; R7 represents hydrogen, alkyl or aryl; R8 represents halogen, alkyl, amino, acylamino, arylamino or aryl group; R9 represents hydrogen, hydroxyl, amino, halogen, alkyl, alkoxy, aryloxy, monoalkylamino, dialkylamino, acylamino, arylamino, groups; m is an integer and is in the range of 0 to 4; n is an integer and is in the range of 0 to 4; p represents an integer of 1 or 2; with a proviso that when R1 represents hydrogen R2 is not hydrogen.

2. Novel pyrimidones of the formula (I) as claimed in claim 1, wherein the ring systems represented by A and B are selected from phenyl, naphthyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl, piperazinyl, pyridyl, thienyl, furyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyrimidinyl, benzopyranyl, benzofuranyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, benzopyrrolyl, benzoxadiazolyl, benzothiadiazolyl, quinolinyl, isoquinolinyl, benzothienyl, benzofuranyl or indolyl.
3. Novel pyrimidones of the formula (I) as claimed in claim 1, which are selected from:
5-Cyano-2-(4-chlorophenyl)-4-(methylthio)-l-[4-(methylthio)phenyl]-6-oxo-l,6-dihydropyrimidine;
5-Cyano-2-(4-fluorophenyl)-4-(methylthio)-l-[4-(methylthio)phenyl]-6-oxo-l,6-dihydropyrimidine;
5-Cyano-2-phenyl-4-(methylthio)-l-[4-(methylthio)phenyl]-6-oxo-l,6-dihydropyrimidine; 5-Cyano-2-(trifluoromethylphenyl)-4-(methylthio)-l-[4-(methylthio)phenyl]-6-oxo-
1,6-dihydropyrimidine;
5-Cyano-2-[(4-methylthio)phenyl]-4-(methylthio)-l-[4-fluorophenyl]-6-oxo-l,6-dihydropyrimidine;
5-Cyano-l-(4-methylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-l,6-dihydropyrimidine
5-Cyano-2-[(4-methylsulphonyl)phenyl]-4-(methylthio)-l-[4-methylphenyl]-6-oxo-1,6-dihydropyrimidine;
5-Carboxy-2-[(4-methylthio)phenyl]-4-(methylthio)-1 -[4-methylphenyl]-6-oxo-1,6-dihydropyrimidine ;

5-Cyano-l-(4-isopropylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-l,6-dihydropyrimidine;
5-Cyano-l-(3,4-dimethylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-l,6-dihydropyrimidine;
5-Cyano-l-{4-isopropylphenyl)-2-[4-(methylsulfonyl)phenyl]-4-(methylthio)-6-oxo-1,6-dihydropyrimidine;
5-Cyano-l-(3,4-dimethylphenyl)-2-[4-(methylsulfonyl)phenyl]-4-(methylthio)-6-oxo-1,6-dihydropyrimidine;
5-Cyano-l-(3,4,5-trimethoxyphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine;
5-Cyano-l-(4-ethylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-l,6-dihydropyrimidine;
l-(4-Bromophenyl)-5-cyano-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-l,6-dihydropyrimidine;
5-Cyano-l-(4-methoxyphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-l,6-dihydropyrimidine;
5 -Cyano-1 -(4-fluorophenyl)-4-(methylthio)-2-phenyl-6-oxo-1,6-dihydropyrimidine; l-{4-Chlorophenyl)-5-cyano-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-l,6-dihydropyrimidine;
5-Cyano-l-(2,4-dimethylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-l,6-dihydropyrimidine;
5-Cyano-2-(4-methylphenyl)-4-(methylthio)-l-[4-(methylthio)phenyl]-6-oxo-l ,6-dihydropyrimidine;
5-Cyano-l-(4-methoxyphenyi)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-l,6-dihydropyrimidine;
l-(4-tert-ButylphenyI)-5-cyano-4-(methylthio)-2-[4-(methyIthio)phenyl]-6-oxo-l,6-dihydropyrimidine;

5-Cyano-l-(4-methylphenyl)-4-(methylthio)-6-oxo-2-phenyI-l,6-dihydropyrimidine;
l-(4-n-Butylphenyl)-5-cyano-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-l,6-
dihydropyrimidine;
5-Cyano-l-(4-fluorophenyl)-4-(methylthio)-6-oxo-2-pyridin-4-yl-l,6-
dihydropyrimidine;
5-Cyano-l-(4-fluorophenyl)-4-(methylthio)-6-oxo-2-pyridin-3-yl-l,6-
dihydropyrimidine;
5 -Cyano-4-(methylthio)-1 -[4-(methylthio)phenyl]-6-oxo-2-pyridin-3-yl-1,6-
dihydropyrimidine;
5-Cyano-4-(methylthio)-l-[4-(raethylthio)phenyl]-6-oxo-2-pyridin-4-yl-l,6-
dihydropyrimidine;
5-Cyano-1 -(4-fluorophenyl)-4-(methylthio)-6-oxo-2-pyridin-2-yl-1,6-
dihydropyrimidine;
5-Cyano-4-(methylthio)-l-[4-(methylthio)phenyl]-6-oxo-2-pyridin-2-yl-l,6-
dihydropyrimidine;
5-Cyano-4-(methylthio)-l-(4-methoxyphenyl)-6-oxo-2-pyridin-2-yl-l(6-
dihydropyrimidine;
5-Cyano-4-(methylthio)-l-(3,4-dimethylphenyl)-6-oxo-2-pyridin-2-yl-l,6-
dihydropyrimidine;
5-Cyano-4-(methylthio)-l-(4-ethylphenyl)-6-oxo-2-pyridin-2-yl-l,6-
dihydropyrimidine;
5-Cyano-4-(methylthio)-l-(4-methylphenyl)-6-oxo-2-pyridin-2-yl-l,6-
dihydropyrimidine;
5-Cyano-4-(methylthio)-l-(4-ethoxyphenyl)-6-oxo-2-pyridin-4-yl-l,6-
dihydropyrimidine;
5-Cyano-4-(methylthio)-1 -(4-methylphenyl)-6-oxo-2-pyridin-4-yl-1,6-
dihydropyrimidine;

5-Cyano-4-(methylthio)-l-(4-isopropylphenyl)-6-oxo-2-pyridin-4-yl-l,6-
dihydropyrimidine;
5-Cyano-4-(methylthio)-l-(4-ethylphenyl)-6-oxo-2-pyridin-3-yl-l,6-
dihydropyrimidine;
5 -Cyano-4-(methylthio)-1 -(3,4-dimethylphenyl)-6-oxo-2-pyridin-3-yl-1,6-
dihydropyrimidine;
5-Cyano-4-(methylthio)-l-(4-methoxyphenyl)-6-oxo-2-pyridin-3-yl-l,6-
dihydropyrimidine;
Ethyl l-(4-methylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-l,6-
dihydropyrimidine-5-carboxylate;
Ethyl l-(4-fluorophenyl)-4-(raethylthio)-2-[4-(methylthio)phenyl]-6-oxo-l,6-
dihydropyrimidine-5-carboxylate;
Ethyl 2-(4-fluorophenyl)-4-(methylthio)-l-[4-(methylthio)phenyl]-6-oxo-l,6-
dihydropyrimidine-5-carboxylate;
5-Carboxamido-l-(4-methylphenyl)-4-(memylsulfonyl)-2-[4-
(methylsulfonyl)phenyl]-6-oxo-l,6-dihydropyrimidine;
5-Carboxamido-l-(4-methylphenyl)-2-[4-(methylsulfonyl)phenyl]-6-oxo-4-
piperazin-1 -yl-1,6-dihydropyrimidine;
5-Carboxamido-4-(methylaraino)-l-(4-methylphenyl)-2-[4-(methylsulfonyl)phenyl]-
6-oxo-l,6-dihydropyrimidine;
5-Carboxaraido-l-(4-methyIphenyl)-2-[4-(methylsulfonyl)phenyl]-4-morpholin-4-yl-
6-oxo-1,6-dihydropyrimidine;
5-Carboxamido-2-(4-fluorophenyl)-4-(methylsulfonyl)-l-[4-
(methylsulfonyl)phenyl]-6-oxo-1,6-dihydropyrimidine;
5-Carboxamido-2-(4-fluorophenyl)-4-(methylamino)-l-[4-(methylsulfonyl)phenyl]-
6-oxo-1,6-dihydropyrimidine;

5-Carboxamido-2-(4-fluorophenyl)-l-[4-(methylsulfonyl)phenyl]-4-morpholin-4-yl-6-oxo-1,6-dihydropyrimidine;
5-Carboxamido-1 -(3,4-dimethylphenyl)-4-(methylsulfonyl)-2-[4-(methylsulfonyl)phenyl]-6-oxo-l,6-dihydropyrimidine;
5-Cyano-2-(4-fluorophenyl)-4'hydroxy-l-[4-(methylsulfonyl)phenyl]-6-oxo-l,6-dihydropyrimidine;
5-Cyano-l-(3,4-dimethylphenyl)-4-hydroxy-2-[4-(methylsulfonyl)phenyl]-6-oxo-l,6-dihydropyrimidine;
5-Cyano-4-(methylamino)-l-(4-methylphenyl)-2-[4-(methylthio)phenyl]-6-oxo-l,6-dihydropyrimidine;
5-Cyano-l-(3,4-dimethylphenyl)-4-(raethylamino)-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine;
5-Cyano-2-(4-fluorophenyl)-4'(methylamino)-1 -[4-(tnethylthio)phenyl]-6-oxo-1,6-dihydropyrimidine;
4-[5-Cyano-l-(3,4-dimethylphenyl)-4-(methylthio)-6-oxo-l,6-dihydropyrimidin-2-yl]benzenesulfonyl chloride;
4-[5-Cyano-2-(4-ethoxyphenyl)-4-(methylthio)-6-oxopyrimidin-l(6/^)-yl]benzenesulfonyl chloride;
4-[5-Cyano-l-(4-methylphenyl)-4-(methylthio)-6-oxo-l,6-dihydropyrimidin-2-yl]benzenesulfonamide;
Af-({4-[5-Cyano-l-(4-methylphenyl)-4-(memylthio)-6-oxo-l,6-dihydropyrimidin-2-yl]phenyl} sulfonyl)acetamide;
A^-({4-[5-Cyano-l-(3,4-dimethylphenyl)-4-{methylthio)-6-oxo-l,6-dihydropyrimidin-2-yl]phenyl} sulfonyl)acetamide;
/V_( {4-[5-Cyano-1 -(4-methylphenyl)-4-(methylthio)-6-oxo-1,6-dihydropyrimidin-2-yl]phenyl}sulfonyl)-2,2,2-trifluoroacetamide;

A/-({4-[5-Cyano-l-(3,4-dimethylphenyl)-4-(methylthio)-6-oxo-l,6-dihydropyrimidin-
2-yl]phenyl}sulfonyl)-2,2,2-trifluoroacetamide;
N-( {4-[5-Cyano-1 -(4-methylphenyl)-4-(methylthio)-6-oxo-1,6-dihydropyrimidin-2-
yl]phenyl}sulfonyl)benzamide and
A^-({4-[5-Cyano-l-(3,4-dimethylphenyl)-4-(methylthio)-6-oxo-l>6-dihydropyrimidin-
2-yI]phenyl}sulfonyl)benzamide.
4. A process for the preparation of novel pyrimidones of the formula (I)

their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, and their pharmaceutically acceptable salts, wherein X represents oxygen, sulfur or NR, wherein R represents hydrogen, hydroxyl, acyl, alkyl, alkoxy, aryl, amino, hydroxylamino, alkylamino, arylamino, acylamino, alkoxyamino group; the rings represented by A and B are selected from aryl or heteroaryl; R1 and R3 may be same or different and independently represent hydrogen, SR7, S(0)pR8; R2 and R4 may be same or different and independently represent hydrogen, halogen, hydroxyl, nitro, cyano, azido, nitroso, amino, formyl, alkyl, haloalkyl, acyl, alkoxy, monoalkylamino, dialkylamino, acylamino, alkoxycarbonyl, SR, S(0)pR , alkoxyalkyl groups or carboxylic acids or its derivatives; R5 and R may be same or different and independently represent hydrogen, halogen, hydroxyl, nitro, cyano, azido, nitroso, amino, formyl, alkyl, aryl, aralkyl, haloalkyl, acyl, alkoxy, aryloxy, aralkoxy, heteroaryl, heterocyclyl, monoalkylamino, dialkylamino, acylamino, alkoxycarbonyl, SR7, S(0)pRa, alkoxyalkyl groups or COR9; R7 represents hydrogen, alkyl or aryl; R8 represents halogen, alkyl, amino, acylamino, arylamino or aryl group; R9 represents hydrogen, hydroxyl, amino, halogen, alkyl, alkoxy, aryloxy,

monoalkylamino, dialkylamino, acylamino, arylamino, groups; m is an integer and is in the range of 0 to 4; n is an integer and is in the range of 0 to 4; p represents an integer of 1 or 2; with a proviso that when R1 represents hydrogen R2 is not hydrogen, which comprises reacting a compound of the formula (la)

their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, and their pharmaceutically acceptable salts, wherein X represents oxygen, sulfur or NR, wherein R represents hydrogen, hydroxyl, acyl, alkyl, alkoxy, aryl, amino, hydroxylamino, alkylamino, arylamino, acylamino, alkoxyamino group; the rings represented by A and B are selected from aryl or heteroaryl; R and R may be same or different and independently represent hydrogen, SR , S(0)pR ; R and R4 may be same or different and independently represent hydrogen, halogen, hydroxyl,

nitro, cyano, azido, nitroso, amino, formyl, alkyl, haloalkyl, acyl, alkoxy, monoalkylamino, dialkylamino, acylamino, alkoxycarbonyl, SR7, S(0)pR8, alkoxyalkyl groups or carboxylic acids or its derivatives; R5 and R6 may be same or different and independently represent hydrogen, halogen, hydroxyl, nitro, cyano, azido, nitroso, amino, formyl, alkyl, aryl, aralkyl, haloalkyl, acyl, alkoxy, aryloxy, aralkoxy, heteroaryl, heterocyclyl, monoalkylamino, dialkylamino, acylamino, alkoxycarbonyl, SR7, S(0)pR8, alkoxyalkyl groups or COR9; R7 represents hydrogen, alkyl or aryl; R8 represents halogen, alkyl, amino, acylamino, arylamino or aryl group; R represents hydrogen, hydroxyl, amino, halogen, alkyl, alkoxy, aryloxy, monoalkylamino, dialkylamino, acylamino, arylamino, groups; m is an integer and is in the range of 0 to 4; n is an integer and is in the range of 0 to 4; p represents an integer of 1 or 2; with a proviso that when R1 represents hydrogen R2 is not hydrogen, which comprises reacting a compound of the formula (Ic)

where R represent (CrC3) alkyl group and all other symbols are as defined above, with a compound of the formula (Id)

wherein all symbols are as defined above, to produce a compound of formula (I)
6. A process for the conversion of novel pyrimidones of the formula (I) as
claimed in claim 1,


wherein any one of the groups R1 and R3 represent SR7, wherein R7 represents alkyl or aryl and all other symbols are as defined in claim 1, to novel pyrimidones of the formula (I) wherein any one of the groups R1 and R3 represent S(0)pR8, where p represents 1 or 2 and R8 represents alkyl or aryl, and all other symbols are as defined above, using an oxidizing agent.
7. A process for the conversion of novel pyrimidones of the formula (I) as
claimed in claim 1,
wherein any one of the groups R and R represent S(0)pR , where p is 1 or 2, R represents alkyl or aryl and all other symbols are as defined in claim 1, to novel pyrimidones of the formula (I) wherein any one of the groups Rl and R3 represent S(0)pR8, where p is 1 or 2, R8 represents amino group and all other symbols are as defined in claim 1.
8. A process for the conversion of novel pyrimidones of the formula (I) as
claimed in claim 1,

wherein either of the groups R1 or R3 represent S(0)pRa, wherein R8 represents amino group and p represents an integer of 1 or 2 and all other symbols are as defined in claim 1, which comprises reacting compound of formula (Ie)

wherein R1 or R3 represents hydrogen and all other symbols are as defined in claim 1, with chlorosulfonic acid and ammonia. -
9. A compound of formula (lb)

their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, and their pharmaceutically acceptable salts, wherein R1 and R3 may be same or different and independently represent hydrogen, SR7, S(0)pR8; R2 and R4 may be same or different and independently represent hydrogen, halogen, hydroxyl, nitro, cyano, azido, nitroso, amino, formyl, alkyl, haloalkyl, acyl, alkoxy, monoalkylamino, dialkylamino, acylamino, alkoxycarbonyl, SR7, S(0)pR8, alkoxyalkyl groups or carboxylic acids or its derivatives; R7 represents hydrogen, alkyl or aryl; R8 represents halogen, alkyl, amino, acylamino, arylamino or aryl group; m is an integer and is in the range of 0 to 4; n is an integer and is in the range of 0 to 4; p represents an integer of 1 or 2.
10. A process for the preparation of compound of formula (lb) as defined in claim
9, which comprises, methylating the compound of formula (Ib-2)


their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, and their pharmaceutically acceptable salts, wherein R1 and R3 may be same or different and independently represent hydrogen, SR7, S(0)pR8; R2 and R4 may be same or different and independently represent hydrogen, halogen, hydroxyl, nitro, cyano, azido, nitroso, amino, formyl, alkyl, haloalkyl, acyl, alkoxy,
7 Q
monoalkylamino, dialkylamino, acylamino, alkoxycarbonyl, SR, S(0)pR, alkoxyalkyl groups or carboxylic acids or its derivatives; R7 represents hydrogen,

alky] or aryl; R represents halogen, alky], amino, acylamino, arylamino or aryl group; m is an integer and is in the range of 0 to 4; n is an integer and is in the range of 0 to 4; p represents an integer of 1 or 2. 13. A process for the preparation of compound of formula (Id) as defined in claim

as defined in claim 1 and a pharmaceutically acceptable carrier, diluent, excipient or solvate.
15. A pharmaceutical composition as claimed in claim 14, in the form of a tablet, capsule, powder, syrup, aerosol, solution or suspension.
16. A pharmaceutical composition which comprises a compound as claimed in claim 3 and a pharmaceutically acceptable carrier, diluent, excipient or solvate.
17. A pharmaceutical composition as claimed in claim 16, in the form of a tablet,
capsule, powder, syrup, aerosol, solution or suspension.
18. Use of a compound of formula (I) as claimed in claim 1, for the prophylaxis or
treatment of rheumatoid arthritis; osteophorosis; multiple myeloma; uveititis; acute

and chronic myelogenous leukemia; ischemic heart disease, atherosclerosis, cancer, ischemic-induced cell damage, pancreatic p cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic Thinitis; ulcerative colitis; anaphylaxis; contact dermatitis; asthma; muscle degeneration; cachexia; type I and type II diabetes; bone resorption diseases; ischemia reperfusion injury; atherosclerosis; brain trauma; multiple sclerosis; cerebral malaria; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection. HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses (including HSV-1, HSV-2), and herpes zoster infection.
19. Use of a compound as claimed in claim 3, for the prophylaxis or treatment of rheumatoid arthritis; osteophorosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; ischemic heart disease, atherosclerosis, cancer, ischemic-induced cell damage, pancreatic P cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; asthma; muscle degeneration; cachexia; type I and type II diabetes; bone resorption diseases; ischemia reperfusion injury; atherosclerosis; brain trauma; multiple sclerosis; cerebral malaria; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection. HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses (including HSV-1, HSV-2), and herpes zoster infection.
20. Use of a composition as claimed in claim 14, for the prophylaxis or treatment of rheumatoid arthritis, Pagets disease, osteophorosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic p cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative

colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfijsion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection.
21. Use of a compound of formula (I) as claimed in claim 1 for lowering plasma concentrations of either or both TNF-cc and IL-1.
22. Use of a compound as claimed in claim 3 for lowering plasma concentrations of either or both TNF-a and IL-1.
23. Use of a composition as claimed in claim 14 for lowering plasma concentrations of either or both TNF-a and IL-1.
24. Use of a compound of formula (I) as claimed in claim 1 for lowering plasma concentrations of either or both IL-6 and IL-8.
25. Use of a compound as claimed in claim 3 for lowering plasma concentrations of either or both IL-6 and IL-8.
26. Use of a composition as claimed in claim 14 for lowering plasma concentrations of either or both IL-6 and IL-8.
27. Use of a compound of formula (I) as claimed in claim 1 for the prophylaxis or treatment of a pain disorder.
28. Use of a compound as claimed in claim 3 for the prophylaxis or treatment of a pain disorder.
29. Use of a composition as claimed in claim 14 for the prophylaxis or treatment of a pain disorder.
30. Use of a compound of formula (I) as claimed in claim 1 for decreasing prostaglandin production.

31. Use of a compound as claimed in claim 3 for decreasing prostaglandin production.
32. Use of a composition as claimed in claim 14 for decreasing prostaglandin production.
33. Use of a compound of formula (I) as claimed in claim 1 for decreasing cyclooxygenase enzyme activity.
34. Use of a compound according to claim 33, wherein the cyclooxygenase enzyme is COX-2 or COX-3.
35. Use of a compound as claimed in claim 3 for decreasing cyclooxygenase enzyme activity.
36. Use of a compound according to claim 35, wherein the cyclooxygenase enzyme is COX-2 or COX-3.


31. Use of a compound as claimed in claim 3 for decreasing prostaglandin
production.
32. Use of a composition as claimed in claim 14 for decreasing prostaglandin
production.
33. Use of a compound of formula (I) as claimed in claim 1 for decreasing cyclooxygenase enzyme activity.
34. Use of a compound according to claim 33, wherein the cyclooxygenase enzyme is COX-2 or COX-3.

35. Use of a compound as claimed in claim 3 for decreasing cyclooxygenase enzyme activity-
36. Use of a compound according to claim 35, wherein the cyclooxygenase enzyme is COX-2 or COX-3.